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GENERAL INTRODUCTION 
The primary focus of these studies is on the regula­
tion by the growth modulators transforming growth factor p 
(TGF-p), phorbol 12-myristate 13-acetate (PMA), and retino-
ic acid of the expression of type 1 plasminogen activator 
inhibitor (PAI-1) and of another protein, as yet undefined 
functionally, that we call "Inhibitor-induced protein, Mj. 
73,000" (IIP73). The project was designed to characterize 
the effects of the growth modulators TGF-/3, PMA and retino-
ic acid on the synthesis and secretion of PAI-1 and IIP73 
and to define the involvement of the cyclic adenosine 
monophosphate (cAMP) second messenger and protein kinase C 
signalling pathways on growth modulator-induced secreted 
protein expression and cellular proliferation. 
TGF-/S is a dimeric Mj. 25,000 secreted protein that is 
produced by a wide variety of cells and tissues from both 
normal and transformed sources (1,2). The TGF-/3 cDNA 
sequence, confirmed by N-terminal sequencing, shows that 
TGî'-/3 is made as a 390 amino acid precursor that is proc­
essed into its 112 amino acid monomer form (3). TGF-jS is 
found in the highest concentrations in bone and platelets 
(4,5) although most cells in culture secrete it in a bio­
logically inactive form. TGF-/3 is secreted by cells in an 
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inactive (latent) form which can be activated (gaining the 
capability of binding to the TGF-/3 receptor) by exposure to 
acid, alkali, or an exogenous proteinase such as plasmin 
(6,7). The latent TGF-)S is unable to bind to the TGF-# 
receptor (8) and the activation process presumably disrupts 
the TGF-/3 precursor quaternary structure to allow 
interaction with the receptor. The rate of the activation 
process may be an important regulatory step in control of 
TGF-j9 action. Because there are a limited number of 
acidic/alkali microenvironments found in vivo (such as 
around osteoclasts or in wounded tissue), the activity of 
exogenous proteinases may be the key in vivo activator. 
TGF-j3 is found in the plasma bound by a2-macroglobulin 
and removed at the liver where it is metabolized (9). 
There have been three high affinity (picomolar range) 
receptors for TGF-/3 identified, the Mj. 65,000 type I, Mj. 
85,000 type II, and the heparin/chondroitin sulfate-linked 
Mj- 280,000 type III receptor (10). Unlike the EGF and PDGF 
receptors, the TGF-/3 receptors do not appear to have any 
tyrosine kinase activity (11). There are at least three 
forms of TGF-# based on the subunit composition of the 
monomers. TGF-#1 is found in human and porcine platelets, 
is also known as cartilage-inducing factor A, and is com­
posed of homodimers of the TGF-^l chain. TGF-02 is com­
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posed of homodimeric TGF-/92 chains that have about 70% 
amino acid homology to the TGF-/51 chain and is found in 
porcine platelets, is also known as cartilage-inducing 
factor B and as the BSC-1 growth inhibitor (polyergin). 
TGF-#1.2 is a heterodimer of the TGF-/31 and TGF-)92 chains 
and is found in small quantities in porcine platelets (12). 
Type I and type II receptors have approximately 10 times 
more affinity for TGF-/31 than for TGF-/32, and an 
intermediate affinity for TGF-/31.2. The three TGF-/3s have 
similar affinities for the type III receptor (13). It 
appears that the type I TGF-/3 receptor mediates the TGF-/3 
signal for growth inhibition and fibronectin production. 
This is demonstrated by results from studies of an 
epithelial cell line that does not express the type I 
receptor (14). In most cases, the biological potency of 
the TGF-jSs on inhibition of proliferation correlated with 
their ability to bind to the type I receptor (13). The 
specific roles of the TGF-j8 type II and type III receptors 
are not well defined. 
There are several other growth inhibitory polypeptides 
that are related to TGF-/9 and that are important in 
development and differentiation of organs. Mulleriah 
inhibitory substance causes inhibition of meiosis and 
regression of Mullerian ducts (female rudiments) in the 
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male embryo (15), and inhibin regulates the secretion of 
pituitary follicle-stimulating hormone which affects 
estrogen and progesterone production by ovary and 
testicular cells (16). The decapentaplegic gene complex of 
Drosophila is related to the TGF-# cDNA sequence and is a 
regulator of embryonic development of Drosophila larva (17) 
as is the Vgl maternal mRNA from Xenopus oocytes which 
probably regulates cell conversion to endoderm and forma­
tion of mesenchyme (18). The functions of the members of 
this family of proteins indicates a role for TGF-/3 in vivo 
regulating development. 
TGF-/3 can stimulate DNA synthesis in some fibroblast 
cell lines including AKR-2B fibroblasts but the stimulation 
is probably due to TGF-/3-induced expression of the c-sis 
gene and its protein product, the B chain of platelet 
derived growth factor (PDGF) (19). PDGF is a potent mito­
gen for many cells in culture. TGF-/3 is a potent inhibitor 
of cell growth in a variety of cells including epithelial 
cells (20) but, because TGF-/3 is found in the latent form 
(6) and because the TGF-jS activation process in the in vivo 
microenvironment is not fully elucidated, the role of TGF-)3 
in growth inhibition in vivo is still not fully understood. 
TGF-/S can be a potent differentiation agent. It 
stimulates fetal muscle mesenchymal cells to differentiate 
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into bone cells (4), induces terminal differentiation of 
human bronchial epithelial cells into squamous cells (21) 
and prevents myoblast differentiation (22). 
One of the major roles of TGF-# could be in regulation 
of tissue repair, tissue remodeling and extracellular 
matrix (ECM) formation, such as that which would accompany 
wounding, injury, embryonic development or tumor growth. 
TGF-0, injected into rats or mice, induces formation of 
granulation tissue (including formation of new blood ves­
sels) and collagen fibrils (23). When applied topically to 
incisional wounds it accelerates wound repair and strength 
of the scar tissue (24). 
TGF-iS stimulates rapid synthesis and deposition of ECM 
proteins such as fibronectin and collagen (25), tenascin 
(26), and proteoglycans (27). TGF-# also induces cultured 
osteoblasts (which, in vivo, are important in the formation 
of new bone) to proliferate. These same cells also synthe­
size and secrete TGF-/3 suggesting that some type of auto­
crine or paracrine stimulatory paths could be present (28). 
The ECM provides important structural support as well as 
regulates cell adhesion, cell migration and cell morphology 
and can participate in process of cellular proliferation 
and differentiation (29). TGF-p can also regulate the 
activities of proteinases through stimulation of synthesis 
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and secretion of proteinase inhibitors such as type 1 
plasminogen activator inhibitor (PAI-1) (30,31) which 
inactivates urokinase plasminogen activator (u-PA) and 
tissue type plasminogen activator (t-PA) (32), and through 
stimulation of synthesis and secretion of tissue inhibitor 
of metalloproteinases (TIMP) which inactivates neutral 
proteinases such as collagenase and stromelysin (33). The 
implications of TGF-/3's regulation of the ECM will be 
discussed later. 
As well as stimulating synthesis of ECM proteins, TGF-
/3 can modulate the activities of several proteinases that 
can degrade the ECM. TGF-# inhibits secretion of cathepsin 
L (34) and urokinase plasminogen activator (u-PA) (32). 
TGF-/3 also regulates the action of other growth factors on 
the synthesis of proteinases. TGF-/3 can also prevent the 
EGF-induced expression of rat transin (a stromelysin-like 
proteinase) (35), the EGF-induced expression of collagenase 
(33), and the EGF-induced expression of cathepsin L (34). 
Phorbol 12-myristate 13-acetate (PMA; also known as 
TPA) is a potent tumor promoter that acts as an analog of 
diacylglyerol and is used in jya vitro studies because it 
binds to and activates the Ca**- and phospholipid-dependent 
protein kinase C (PKC) and in some cells PMA can mimic 
growth factor effects on proliferation and gene expression 
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(36,37). PMA was first isolated from the seed oil of the 
plant Croton tialium i (Europhorbiaceae) (38). While PMA's 
tumor promoting activity provided the original motivation 
for our studying phorbol ester activities, we were 
interested in using PMA to define the role PKC plays in the 
mediation of growth modulator induction of several secreted 
proteins. 
Protein kinase C is an enzyme which has at least seven 
isoforms with distinct patterns of tissue expression 
through which it is possible that differential processing 
of extracellular signals results in a variety of physiolgi-
cal responses (39). Levels of PKC are highest in brain but 
are also high in lung. Activation of PKC results in auto-
phosphorylation of PKC as well as phosphorylation on serine 
and threonine residues of proteins including the EGF recep­
tor (40). 
The effects of PMA and PKC are probably mediated at 
the nuclear level by the TPA responsive element (TRE). The 
TRE consensus sequence is 5'-TGAGTCA-3' (41). The activity 
of several genes such as the human metallothionein 11^, 
SV40 enhancer and IL-2 are regulated by the presence of a 
TRE in the upstream region of the promoter (42,43,44). The 
enhancer binding protein AP-1 binds to the TRE (45). Thus, 
the results of PMA activation of PKC can be mediated at the 
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nuclear level by cis-actina responsive elements and the 
specific response element binding protein, AP-1. 
Because TGF-/3 is an inhibitor of proliferation and 
because TGF-/3 can specifically induce expression of compo­
nents of the ECM, we wondered whether retinoic acid, which 
can also inhibit proliferation, especially of tumor cells, 
and induces expression of extracellular matrix components, 
could regulate the expression of secreted proteins in a 
manner similar to TGF-/9. Retinoic acid, the carboxylic 
acid form of vitamin A, like TGF-/8, can also regulate cell 
growth, proliferation and differentiation. Retinoic acid 
can regulate proliferation in a variety of cell lines 
including Leydig cells (46), mammary tumor cells (47), and 
fibroblasts (48). It also induces terminal differentiation 
of the human promyelocytic leukemia HL-60 cell lines to 
mature granulocytes and F9 embryonal teratocarcinoma stem 
cells to parietal endoderm and keratinocytes (49,50,51). 
There is a cytoplasmic retinoic acid binding protein 
(52) and the cDNAs for several nuclear retinoic acid recep­
tors have been cloned (53,54,55). The description of the 
retinoic acid receptors as nuclear ligand-inducible tran­
scription factors provides molecular evidence for retinoid 
activity on transcription events. 
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Retinoic acid has been hypothesized to be a morphogen 
that diffuses across the posterior limb bud, setting up a 
retinoic acid concentration gradient to which specific 
cells respond differently and differentiate into specific 
digits and tissues (56). Recent research has identified 
retinoids in chick limb buds (57) and it has been seen that 
application of retinoids from an implant results in a 
concentration gradient implying that the gradient does 
regulate limb bud cell expression (58). The retinoic acid 
concentration gradient is proposed to activate specific 
gene transcription mediated by the nuclear retinoic acid 
receptor based on the retinoid concentration gradient. 
Differential gene expression in the limb bud would result 
in the discrete pattern of limb structures (57). 
TGF-p and retinoic acid can regulate expression of 
components of the extracellular matrix such as collagen and 
fibronectin (25,59), glycosaminoglycans (60,61) and can 
regulate expression of proteases such as plasminogen acti­
vator (62,63). 
TGF-p can inhibit proteolytic activity by regulating 
expression of proteinases and proteinase inhibitors. 
Proteolysis is a highly regulated activity within mammalian 
systems and overexpression of proteolytic activity is 
commonly found in cancer. Plasmin is a widely studied. 
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broad spectrum proteinase formed by the proteolytic proc­
essing of the inactive zymogen plasminogen into plasmin by 
plasminogen activators. 
Two molecularly different, functionally similar plas­
minogen activators have been described. Tissue-type plas­
minogen activator (t-PA) is more abundant in plasma while 
urokinase plasminogen activator (u-PA) is more abundant in 
urine. Both are widely distributed in body fluids and 
tissues and they can be made and secreted simultaneously by 
the same cells (64). Because of their primary tissue 
localization, t-PA is regarded as a mediator of fibrinolyt­
ic activity in the bloodstream while u-PA is regarded as 
the cellular PA with a role in reproduction, inflammation, 
and cell migration as well as a role in tissue inflammation 
and cancer (64,65). 
Production of PAs by cell culture systems can be 
altered by hormones such as glucocorticoids, steroid hor­
mones, vasopressin and retinoic acid as well as growth 
factors (64,65). PAs, especially u-PA, can contribute to 
cell proliferation by binding to specific PA receptors and, 
through local proteolytic activity, decreasing the cell's 
adhesion to the extracellular matrix allowing for cell 
migration and, in the case of malignancy, invasion 
(64,65,66,67,68). 
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Metalloproteinases, including collagenase and strome-
lysin, alter connective tissue in normal processes such as 
wound healing and uterine resorption and in disease states 
such as tumor invasion and rheumatoid arthritis (69). 
Rheumatoid arthritis is an autoimmune disease in which 
synovial fibroblasts secrete large amounts of collagenase 
and stromelysin which results in destruction of articular 
cartilage and bone (70). Cell stress induced by fusion of 
rabbit synovial fibroblasts with polyethylene glycol in­
creases the synthesis of collagenase and stromelysin mRNA 
(71). Heat shock can also induce synthesis and secretion 
of collagenase and stromelysin. However, 10~®M retinoic 
acid, added just prior to heat shock, prevented the in­
crease in collagenase and stromelysin mRNAs (72). All-
trans retinoic acid can inhibit metalloproteinase synthesis 
induced by a number of agents including PMA and polyethyl­
ene glycol (73). While there is no explanation offered as 
to the role retinoids play in the regulation of collagenase 
and stromelysin induction, it is tempting to speculate that 
the nuclear retinoic acid receptors, acting as transcrip­
tion factors, may be involved. 
Proteinase inhibitors comprise about 10% of plasma 
protein (74) and are made and secreted by a variety of cell 
types (75). t-PA converts plasminogen to plasmin specifi­
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cally at the site of a blood clot (76), and t-PA has been 
developed into a clot dissolving drug used in treating 
coronary blockage (77). It is likely that proteinase 
inhibitors function to control excessive proteolytic action 
in blood clotting, fibrinolysis, tissue remodeling and 
inflammatory processes. It is hypothesized that lack of 
proteolytic control can result in malignancy. 
Plasminogen activator inhibitor is a fast acting 
serine proteinase inhibitor, Mj. 48,000 to 54,000 that can 
regulate the activity of plasminogen activators through 
formation of a 1:1 complex with PA and thus regulate the 
generation of the broad spectrum proteinase, plasmin (78). 
Three classes of plasminogen activator inhibitor have been 
identified including the endothelial cell type 1 plasmino­
gen activator inhibitor (PAI-1) (79), the placental PAI 
(PAI-2) (80) and protease nexin (81). PAI-1 has been 
purified from a variety of sources including endothelial 
cells (79) and platelets (82). PAI-1, after secretion, 
becomes associated with the ECM (83) and presumably protects 
the ECM from degradation by secreted, pericellular 
proteinases. The expression of PAI-1 can be regulated by a 
wide variety of growth modulators such as E6F, F6F, PMA, 
IL-1 and TNF-a (84,85). 
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Platelets are a rich source of growth factors such as 
TGF-/3 and platelet derived growth factor (PDGF). Because 
the most likely location of platelet activation is at sites 
of hemostasis or thrombosis, the role of platelet PAI-l 
could be one of rapid inhibition of fibrinolysis at the 
site of injury to prevent fibrinolysis. The purified PAI-1 
from platelets is 88% active (82). This is in contrast to 
PAI-1 isolated from cell culture conditioned medium which 
is greater than 98% inactive (86). 
PAI-1 alone in a physiological solution has a half-
life of less than 3 h but the half life is greater than 24 
h when associated with its binding protein (87) which is 
vitronectin. Vitronectin is found in the plasma and 
associated with the ECM (88). In the ECM, vitronectin is 
an adhesive protein that promotes the attachment and 
spreading of endothelial cells (89). The association of 
PAI-1 with vitronectin provides a mechanism for extending 
the time after synthesis that PAI-1 can modulate the 
effects of proteinases in both plasma and in association 
with the ECM. 
PAI-1 reacts with both t-PA and u-PA with a second 
order rate constant of about 10^ mol/L~^s~^ (82). The 
PA/PAI-1 complex is SDS-stable and about 110-120 kDa (90). 
While the exact mechanism of the PAI-l/PA reaction is not 
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known it seems logical that the mechanism is like that of 
other serine proteinases in the same superfamily. The 
initial rapid complex formation by protease and protease 
inhibitor is reversible followed by a transition to a more 
stable complex that occurs at a slower rate (91). 
T6F-/3 can stimulate the production of certain 
proteinase inhibitors including TIMP (33) and PAI-1 
(30,31). Thus, TGF-/3 can regulate the proteolytic balance 
of cultured cells by regulation of expression and synthesis 
of both proteinases and specific inhibitors of proteinases. 
The growth inhibitory effects of TGF-jS may be mediated 
through deposition and stabilization of the extracellular 
matrix components via induced synthesis of collagen, fibro-
nectin, laminin, and proteoglycans, decreased sythesis of 
proteinases such as collagenase and plasminogen activator, 
and increased synthesis of proteinase inhibitors such as 
PAI-1 and TIMP. The resulting buildup and stability of ECM 
could serve to increase adherence of cells to the growth 
substratum and decrease proliferative activity. There is 
conflicting evidence as to the role components of the 
extracellular matrix, particularly collagen, play in the 
control of cellular proliferation (92,93,94). There is 
very recent evidence that collagen is the direct mediator 
by which TGF-j9 inhibits the growth of normal rat kidney 
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(NRK) cells in serum-free culture. The growth of NRK cells 
plated on a collagen matrix compared with cells grown on a 
fibronectin or laminin matrix and the growth of cells 
treated with exogenous collagen compared with no treatment 
were inhibited about 50% compared with control cells (95). 
The inhibitory effects of TGF-/9 could be abolished by 
addition of collagenase (95). 
The mechanism of inhibition by collagen or other ECM 
proteins could be through alteration of cell shape (96) or 
through the association of collagen with cell surface 
receptors or other ECM proteins such as fibronectin and 
laminin (97). Lack of collagen or ECM proteins could 
"unmask" receptors allowing interaction with growth 
modulators and thus increasing proliferative potential. 
Whereas the "normal" status of a cell within a tissue is 
one of very limited proliferative activity, a change in the 
proteolytic balance may occur due to autocrine or paracrine 
expression of polypeptide growth factors by cancer cells. 
The growth factors then induce expression of proteinases, 
resulting in increased proteolysis of the ECM. Removal of 
the adhesion proteins or unmasking cell surface growth 
receptors could result in increased proliferation and 
invasiveness of cancer cells. 
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The signal transduction mechanisms through which 
growth modulator signals are mediated are not well under­
stood. Although cellular receptors for TGF-/3, PMA and 
retinoic acid have been found and characterized, their 
intracellular signal pathways have not been identified. 
More than one signalling pathway may be involved in the 
overall cellular response to these growth modulators and 
these pathways could interconnect. We show that cAMP 
levels and activation of PKC can regulate the expression of 
PAI-1. 
cAMP can block TGF-jS-induced induction of c-sis in 
endothelial cells (98) as well as lower expressed levels of 
PAI-1 (99). We were interested in determining whether cAMP 
could regulate the TGF-/3-induced and PMA-induced expression 
of PAI-1. cAMP is an ubiquitous second messenger of hor­
monal signal transduction. Activation of certain receptors 
through ligand interaction can result in association of the 
receptor with a GTP-binding protein that is also associated 
with adenylate cyclase. Activation of the G-protein can 
result in activation of adenylate cyclase and production of 
cAMP (100). The effects of cAMP on cell proliferation and 
specific gene expression are probably mediated by cAMP-
dependent protein kinase (PKA) (101) and at the nuclear 
level by specific DNA sequences (the cAMP response element, 
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CRE, that has a consensus sequence of 5'-T6AC6TCA~3'} found 
in the upstream promoter region of genes such as somatosta­
tin (102), phosphoenolpyruvate carboxykinase (PEPCK) (103), 
and proenkephalin (104), and by the presence of the cAMP 
responsive element binding protein (CREB) (105). However, 
little is known of the PKA substrates that could transfer 
the signal to CREB in the nucleus. Perhaps CREB itself is 
regulated by phosphorylation by PKA. The role of cAMP in 
control of CCL64 cell proliferation and regulation of PAI-1 
gene expression will be discussed later. 
Because we were interested in determining the mecha­
nisms by which TGF-/3 induced expression of PAI-1, as well 
as the mechanism by which TGF-/3 inhibited DNA synthesis, we 
used specific disrupters of signal transduction paths to 
determine those pathways involved in the mediation of TGF-/3 
signal transduction. 
Pertussis toxin, a bacterial toxin isolated from 
Bordetello pertussis. mono-ADP-ribosylates the 41 kDa a-
subunit of the protein associated with adenylate cyclase 
causing disruption of the receptor/effector complex and 
loss of signal transduction potential (106). There is 
evidence that pretreatment of AKR-2B cells with pertussis 
toxin, causes loss of GTPase activity by G^ and also loss 
of cell responsiveness to the proliferative effects of TGF-
18 
j91 (107,108). Therefore, it is hypothesized that the TGF-
iSl signal for proliferation is mediated by G^. We were 
interested in determining whether mediated the TGF-/9-
induced expression of PAI-1 and the TGF-/S-induced inhibi­
tion of DNA synthesis. As will be discussed later, our 
data do not suggest a role for G^ in the TGF-j8-induced 
expression of PAI-1 or in inhibition of DNA synthesis. 
Because proteinase inhibitors such as PAI-1 can play 
an important role in regulation of extracellular proteolyt­
ic activity, and because growth modulators such as TGF-j8 
can regulate synthesis and secretion of both proteinases 
and proteinase inhibitors, we wished to determine whether 
growth modulators affected PAI-1 expression at the level of 
transcription. We also wished to determine whether the 
signal transduction pathways which mediate growth modula­
tor-induced expression of PAI-1 and IIP73 are similar and 
we wished to compare and contrast the regulation of IIP?3 
by TGF-/3, PMA and retinoic acid. 
To approach these problems, we used mammalian cell 
cultures to test the effect of growth modulators on synthe­
sis and secretion of PAI-1 and IIP73. In parallel, we also 
examined the effects of these growth modulators on PAI-1 
mRNA levels and on the rate of initiation of PAI-1 tran­
scription. In addition, using compounds that can alter 
19 
either the cAMP concentration or protein kinase C activity 
within a cell, we attempted to determine the importance of 
these pathways in growth modulator-induced expression of 
PAI-1 and IIP73 and on cellular proliferation. 
20 
SECTION I. 
TGF-/3 SIGNAL TRANSDUCTION PATHWAYS AND TYPE 1 
PLAMINOGEN ACTIVATOR INHIBITOR 
21 
ABSTRACT 
Previously, we showed that transforming growth factor 
p (TGF-jS) and the tumor promoter phorbol 12-myristate 13-
acetate (PMA) induce plasminogen activator inhibitor (PAI-
1) in CCL64 mink lung epithelial cells and BSC-1 monkey 
kidney epithelial cells and that TGF-/S and epidermal growth 
factor (EGF) synergistically induce PAI-1 in CCL64 cells. 
We now show that PAI-1 expression can be regulated 
independently through two different signal transduction 
pathways. Down-regulation of protein kinase C completely 
eliminates PMA-induced synthesis and secretion of PAI-1 in 
both CCL64 and BSC-1 cells with no effect on secreted 
TGF-/3- and EGF-induced PAI-1 levels. Addition of cholera 
toxin, forskolin and dibutyryl cAMP, which are all agents 
that increase the intracellular levels of cAMP, lowered 
both the basal level of PAI-1 expression and the TGF-f and 
PMA- induced levels of PAI-1 but did not alter the fold 
increase of PAI-1 levels by TGF-j9 and PMA. PAI-1 mRNA 
levels in NRK cells were similarly lowered after treatment 
with forskolin and cholera toxin. While basal levels of 
PAI-1 gene transcription were too low to measure, TGF-#-
induced PAI-1 gene transcription in NRK cells was lowered 
by treatment with forskolin as measured by nuclear run-on. 
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The agents also decreased the rate of thymidine 
incorporation equally in the basal and TGF-/3 treated state. 
These results suggest that the level of PAI-1 expression is 
sensitive to high levels of intracellular cAMP and that 
this is a transcriptional effect. However, the 
mechanism(s) by which TGF-# regulates PAI-1 expression and 
DNA synthesis do not involve cAMP and do not contain a 
cAMP-sensitive component. Our results also show that TGF-/3 
induces PAI-1 through a pathway other than that which is 
regulated by protein kinase C. 
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INTRODUCTION 
Control of plasminogen activator by plasminogen 
activator inhibitors may be a key component that regulates 
the conversion of plasminogen to the broad spectrum 
protease, plasmin. In addition to its well known role in 
the fibrinolytic clot breakdown pathway, plasmin degrades 
the protein components of the tissue extracellular matrix. 
There are at least three immunologically distinct 
plasminogen activator inhibitors (1,2,3), one of which is 
the endothelial cell type plasminogen activator inhibitor 
that was designated type 1 plasminogen activator inhibitor 
(PAI-l). PAI-1 is a secreted serine protease inhibitor (Mj. 
48,000-55,000), first purified by van Mourik et al. (4), 
which is ubiquitous in mammalian systems. Especially high 
concentrations of PAI-1 are found in serum and in 
platelets. The complete sequences of both the human mRNA 
and gene are known (5,6) as well as the cDNA sequence from 
rat hepatoma cells (7). While the role of PAI-1 in the 
regulation of fibrinolysis and tissue remodeling is 
becoming increasingly clear, little is known of the signal 
transduction pathway(s) that regulate PAI-1 production. 
PAI-1 levels can be regulated by a variety of compounds 
such as TGF-/S (8,9), glucocorticoids (10), IL-1 (11), and 
PMA (9,12). PAI-1 production can be lowered by agents 
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that increase intracellular cAMP (13). Recent evidence has 
indicated that the effects of T6F-j9 on the expression of c-
sis may be modulated by the cAHP concentration within the 
cell (14) and/or by G-proteins, particularly (15,16). 
Our findings show that 1) PAI-1 levels can be regulated by 
protein kinase C (PKC) but that PKC does not mediate the 
cellular response to TGF-p, 2) agents such as forskolin, 
dibutyryl cAMP, and cholera toxin, which increase cellular 
concentrations of cAMP, block or significantly inhibit both 
the basal and TGF-/S-induced levels of PAI-1 in normal rat 
kidney fibroblast (NRK 49F) cells, near term mink lung 
epithelial (CCL64) cells, African green monkey kidney 
epithelial (BSC-1) cells and mouse embryo fibroblast (AKR-
2B 84A) cells, 3) forskolin lowers the rate of PAI-1 
transcription, 4) cholera toxin and forskolin lower the 
overall rate of incorporation of [^H]thymidine by AKR-2B, 
BSC-1, CCL64 and NRK cells, and 5) agents that increase 
cAMP have no effect on the ability of TGF-fi to induce PAI-1 
expression or DNA synthesis in any of these cell lines. 
These results indicate that the intracellular cAMP level 
determines the basal rate of PAI-1 production and DNA 
synthesis but does not significantly alter the ability of 
these cells to respond to TGF-j9 with DNA synthesis or 
increased PAI-1 gene transcription. 
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MATERIALS AND METHODS 
Materials 
PMA used was from either Sigma or CCR, Inc. Bedford, 
Mass. 4-0-methyl PMA was from CCR. pTGF-/S was purified 
from porcine plasma by the method of Assoian et al. (17). 
GI/TGF-/3 was a gift from Dr. Robert Holley (Salk Institute 
for Biological Studies, La Jolla, CA). Epidermal Growth 
Factor (EGF) was from Collaborative Research. Bovine serum 
albumin (BSA), forskolin, norepinephrine, thrombin, butyric 
acid, dibutyryl cAMP, cholera toxin, pertussis toxin, H7 
protein kinase inhibitor, polyethylene glycol, and 
diethylpyrocarbonate were purchased from Sigma. 
Isoproterenol was from Calbiochem. Human PAI-1 cDNA was 
from Dr. Keld Dan^ (cited in 18), rat PAI-1 cDNA was from 
Dr. Ron Zeheb and Dr. Thomas D. Gelehrter (Univ. of 
Michigan) (7). Random primer kits were from NEN or 
Amersham. Zeta probe nylon membranes were from Bio-Rad. 
X-ray film (XAR- 5) was from Kodak. The Hybrid-Ease 
Chamber was from Hoefer and the slot-blotter was from 
Schleicher and Schuell. Radioisotopes were from New 
England Nuclear. RNasin and RNase-free DNase were from 
Promega. Yeast tRNA was from Boehringer-Mannheim. Non-fat 
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dry milk was from Carnation. All other chemicals and 
reagents were from Fisher Scientific or Sigma. 
Cell Culture and Cell Lines 
All cells were cultured in Dulbecco-Vogt•s modified 
Eagle's medium (DMEM), containing 0.45% glucose and no 
sodium pyruvate (Gibco), with 5-10% calf serum with 10 
units/ml penicillin and 10 /xg/ml streptomycin. The stock 
cell cultures were grown as monolayers on plastic tissue 
culture dishes, at 37°C, in a water-saturated atmosphere, 
with 10% CO2 in air. CCL64 cells were from the American 
Type Culture Collection, the BSC-1 cell line was from Dr. 
Robert Holley (The Salk Institute for Biological Studies, 
La Jolla, CA), the AKR-2B (clone 84A) cell line was from 
Dr. Harold Moses (Vanderbilt University, Nashville, TN), 
and the NRK (clone 49F) cell line was from Dr. Duane Enger 
(Iowa State University, Ames, lA). The mink lung 
epithelial mutant (MLEM) cell line (19) was from Dr. 
Phillip Howe (Vanderbilt University, Nashville, TN), and 
the RIB, TGF-/3 type-1 receptor-minus cell line (20) was 
from Frederick T. Boyd and Dr. Joan Massague (Sloan Ketter­
ing Cancer Center, New York, NY). 
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Labeling with [^®S]methionine 
The [^®S]methionine metabolic labeling method is 
described fully in previous publications (9,21). In brief, 
cells were suspended in DMEM containing 0.2 to 1.0% calf 
serum and plated in 24 well tissue culture dishes. One to 
two days after the cells had attached to the dish, the 
medium was removed and fresh DMEM with 0.2% to 0.5% calf 
serum was added. About 24 h later, additions were made and 
the cells were labeled with [^^S]methionine after the 
indicated incubation time. 
SDS-Polyacrylamide Gel Electrophoresis 
SDS-polyacrylamide gel electrophoresis, fluorography 
and densitometric measurement of [^®S]methionine in the 
protein bands were performed as previously described 
(9,21). The results from densitometer scans were 
normalized to the rate of [^®S]methionine incorporated into 
cellular proteins by dividing the value of the area under 
the peak by the amount of acid- insoluble, [^^S]methionine 
radioactivity in the Nonidet P-40 soluble fraction of the 
cell preparation. 
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Immunoprecipltation 
Samples of medium were immunoprecipitated using 
polyclonal antisera raised against purified proteins and 
Staphylococcus aureus as a carrier according to the 
procedure outlined previously (22). 
[^H]thymidine Incorporation and Labeling Index 
Cover slips with [^H]thymidine-labeled cells were 
prepared as previously described and were quantitated by 
liquid scintillation counting and by determining the 
labeling index (9). 
In vitro transcription/Nuclear Run-On 
In vitro transcription assays were performed with NRK 
and BSC-1 cells using the method of Greenberg and Ziff 
(23,24) with modifications as described by Celano et al. 
(25). Four, 15 cm plates of cells were treated for 2 h 
with growth modulator, washed with phosphate buffered 
saline, scraped from the dish, and pooled. After pelleting 
by centrifugation (800 x g, 2 min, 4°C), the cells were 
resuspended in 10 mM NaCl, 3 mM MgCl2, 10 mM Tris-Cl, pH 
29 
7.4 and pipetted gently to separate the cells. NP-40 was 
added to a final concentration of 0.5% and the cells were 
vortexed briefly, then incubated on ice for 5 min. The 
nuclei were removed by centrifugation (800 x q, 1-2 min, 
4°C) and the supernatant, containing the cytoplasmic RNA 
was removed and saved. The nuclei were washed with 
glycerol storage buffer, centrifuged, and resuspended in 50 
(il glycerol storage buffer. An equal volume of twice-
concentrated reaction buffer was added along with 125-200 
fid [32p]UTP. The reaction was 30 min at 30"C with 
shaking. After the reaction, 200 fil MSB buffer plus 20 U 
RNase-free DNase (Promega) was added and then the mixture 
was incubated 30 min at 30°C. After the incubation, 50-100 
jug yeast tRNA was added along with 60 nl lOx SET buffer (5% 
SDS, 50 mM EDTA, 100 mM Tris-HCl, pH. 7.4 (55)) and 25-50 
fil, 10 mg/ml Protease K. This was mixed and incubated for 
1 h at 37"C. The RNA extraction was exactly according to 
Celano's protocol except using 2 times the volume of 
reagents. After recovery of the RNA, the RNA was dissolved 
in hybridization buffer (50% formamide, 5 times 
concentrated SSPE [Ix SSPE = 0.18 M NaCl, 0.01 M Na2HP04, 
0.001 M EDTA], 1% SDS, 0.5% non-fat dry milk, 0.1 mg/ml 
yeast tRNA, 0.5 mg/ml carrier salmon sperm DNA) at 42°C for 
4 d, and hybridized with cDNAs which had been adsorbed on 
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to Bio-Rad Zeta-probe nylon membranes using a slot-blot 
apparatus. The membranes were washed for 60 min with 4 
changes of 2 times concentrated SSC (Ix SSC = 0.15 M NaCl, 
0.015 M Trisodium citrate) /0.1% SDS at 22'C, then with 0.2 
times concentrated SSC/1% SDS for 1 h at 42"C. The 
membranes were then placed in Saran Wrap and exposed to X-
Ray film between two enhancing screens. The resulting 
autoradiograms were scanned by a densitometer. 
RNA Isolation 
Total RNA was isolated by the method of Chirgwin et 
al. (26). In brief, cells were treated with TGF-jS for 3-4 
hours, washed with phosphate buffered saline, and then were 
lysed using 4M guanidinium isothiocyanate. The lysate was 
vortexed vigorously and then centrifuged through 5.7 M CsCl 
for 18 h at 20'C at 35,000 RPM, SW55 rotor. The RNA was 
removed, precipitated with ethanol and quantified. Twenty 
ng was run in a 1% agarose, 2% formaldehyde with 45 jtxg/ml 
ethidium bromide gel in MOPS buffer (0.2 M MOPS, 0.05 M 
sodium acetate, 0.01 M EDTA). RNA was transferred to Bio-
Rad Zeta Probe membrane in 50 mM NaOH and then was 
hybridized with [^^P]-labelled cDNA in a 40-50% formamide, 
0.36 M NaCl, 0.02 M Na2HP04, 7% SDS, 1% polyethylene glycol 
(20,000 Mj.), 0.05% non-fat dry milk, and 0.33 mg/ml salmon 
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sperm DNA hybridization buffer at 50"C in a Hybrid-Ease 
chamber (Hoefer Scientific) or in heat-sealable bags for 
18-24 h or in 30% formamide, 5 times concentrated SSPE, 1% 
SDS, and 0.3 mg/ml salmon sperm DNA at 42'C. The membrane 
was washed successively with 2 times concentrated SSC 
(22°C), 2 times concentrated SSC/0.1% SDS (22°C), 0.2 times 
concentrated SSC/1.0% SDS at 55"C, and 0.5 times 
concentrated SSC (22°C), covered in Saran Wrap and exposed 
to X-Ray film between two enhancing screens at -70°C. The 
autoradiograms were quantified by scanning densitometry. 
Reverse Zymography 
Reverse zymography was performed on the medium from 
AKR-2B (clone 84A), BSC-1, CCL64 and NRK (clone 49F) cells 
treated with or without TGF-j8, PMA or EGF (27), Following 
electrophoresis, acrylamide gels were soaked for two 
consecutive times in 2.5% Triton X-100 for 30 minutes. The 
gels were blotted thoroughly to remove excess liquid and 
then overlaid on to the surface of freshly prepared fibrin-
agar indicator gels. Fibrin-agar gels contained 1% 
agarose, 25 ng/ml plasminogen, 0.2 units/ml bovine 
thrombin, 2.5 mg/ml human fibrinogen and 0.05 units/ml 
urokinase plasminogen activator. Saran-wrap was placed 
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over the aery1amide gel and "enzymography" was carried out 
at 37"C in a humidified tissue culture incubator. At 
appropriate times (usually 2-4 h after the start of the 
incubation), the acrylamide gels were removed and the 
fibrin-agar indicator gels photographed. All of the cell 
lines used in this study secreted PAI-1 that could be 
measured by this assay. 
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RESULTS 
The Effect of TGF-# and PMA on the Induction of Secreted 
Proteins in AKR-2B, BSC-1, CCL64 and NRK Cells 
Figure lA demonstrates the effects of TGF-/3 and PMA on 
the expression of PAI-1 and other secreted proteins in four 
cell lines; AKR-2B, BSC-1, CCL64 and NRK cells. PAI-1 is 
induced by TGF-# from 3- to 800-fold in these cells with 
the average inductions being 13.9-, 6.0-, 27.4-, and 7.7-
fold respectively for AKR-2B, BSC-1, CCL64 and NRK cells 
(Table 1). PMA induces PAI-1 4.8-fold in BSC-1 cells, 3.1-
fold in NRK cells and about 250-fold in CCL64 cells but 
does not significantly induce PAI-1 in AKR-2B cells. PMA-
induced PAI-1 secreted levels were 6.5- fold greater than 
the levels induced by TGF-/3 in CCL64 cells. Because the 
basal-secreted PAI-1 was too low to be measured in some 
experiments, we could better quantitatively compare the 
PMA-induced PAI-1 secreted levels to the TGF-/3-induced PAI-
1 secreted levels. 
Figure IB demonstrates the effects of TGF-# and PMA on 
PAI- 1 mRNA levels in NRK clone 49F cells. The PAI mRNA 
level was also increased by TGF-/9 and PMA in BSC-1 cells. 
These results demonstrate that increases in mRNA synthesis 
are probably at least in part responsible for higher 
Figure lA. The effect of TGF-)8 and PMA on the induction 
of secreted proteins in AKR-2B, BSC-1, CCL64 
and NRK cells 
AKR-2B cells were preincubated for 2.8 h with or 
without 1 U/ml porcine TGF-# (pTGF-#) or lOng/ml PMA and 
then labeled for 4 h with [^^S]methionine. BSC-1 cells 
were preincubated for 0 h with or without 1 U/ml porcine 
TGF-0 (pTGF-jS) or lOng/ml PMA and then labeled for 6 h with 
[^^S]methionine. CCL64 cells were preincubated for 2.5 h 
with or without 1 U/ml porcine TGF-jS (pTGF-f) or lOng/ml 
PMA and then labeled for 4 h with [^^S]methionine. NRK 
cells were preincubated for 0.5 h with or without 1 U/ml 
porcine TGF-/3 (pTGF-)8) or lOng/ml PMA and then labeled for 
6.25 h with [^^S]methionine. Shown are fluorograms of SDS-
polyacrylamide gels through which [^®S]methionine-labeled 
proteins secreted by these cells had been resolved. PAI-1, 
Cathepsin L/Major Excreted protein (MEP), and a 62/65 kd 
PMA- inducible protein are marked by arrows. The numbers 
on the side of the figure show the positions of the 
molecular weight standards used on this and other gels. 
They were (from top to bottom): /S-galactosidase (116,000), 
bovine serum albumin (67,000), and carbonic anhydrase 
(30,000). -, control; T, porcine TGF-jS; P, phorbol 
myristate acetate. 
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Figure IB. The effect of TGF-/3 and PMA on the level of 
PAI-1 mRNA in NRK cells 
Cells were incubated for 3 h with or without 1 U/ml 
porcine TGF-)S or PMA and then lysed with guanidinium 
isothiocyanate, and total RNA isolated as described in the 
"experimental procedures." The RNA was resolved on a 1% 
agarose/formaldehyde gel, blotted to Zeta-probe membrane 
and probed with rat PAI-1 cDNA. The membrane was exposed 
to X-Ray f>lm between two intensifying screens. Markers on 
the side of the figure represent the position of 28S and 
18S RNA. -, control; T, porcine TGF-/3; P, phorbol myristate 
acetate. 
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TABLE 1. The effect of TGF-fi, PMA, forskolin and cholera toxin 
on the levels of secreted PAI-1 by AKR-2B, BSC-1, 
CCL64 and NRK cells 
PAX -1 62/65 MEP 
Cell line AKR-2B BSC-1 CCL64 NRK NRK AKR-2B 
additions (Fold over Control) 
Control 1.0 (7) 1.0 (14) 1.0 (8) 1.0 (12) 1.0 (8) 1.0 (7) 
TGF-# 13.93(6) 6.03(14) 27.43(8) 7.7^(12) 0.9 (7) 0.8 (6) 
PMA 0.7^(7) 4.03(14) 248.43(7) 3.13(11) 32.43(8) 23.93(7) 
Forsk 0.7 (3) 0.7^(6) 1.3 (3) 0.4^(7) 0.9 (6) 3.9^(3) 
TGF-/3 + Forsk 3.23(3) 3.9^(6) 5.53(3) 2.03(7) nd 3.2^(3) 
PMA + Forsk 1.0 (2) 2.53(3) 8.13(6) 0.73(7) 6.13(7) 40.4^(2) 
Cholera tox. 0.5 (3) 0.4^(2) 1.1 (2) 0.6^(3) 2.4 (2) 7.0^(3) 
TGF-/3 + CT 2.53(3) 4.2^(3) 14.9 (3) 2.8^(3) nd 6.7 (2) 
PMA + CT 0.7 (2) 3.8®(2) nd 3.5 (2) 30.3 (2) 64.3 (2) 
All cells were grown as described in Figure 1. Cells treated 
with cholera toxin or pertussis toxin were preincubated with CT or PT 
for 4-5 h prior to addition of TGF-^, PMA or forskolin, incubated for 
2-3 h and then labeled with [^®S]methionine. The amount of acid-
insoluble [^®S]methionine incorporated by the cells was measured as 
described in Experimental Procedures. Each value is the average of 2 
to 14 experiments with two independent estimates for each experiment. 
The paired Students t-test was used for statistical analysis. The 

All cells were grown as described in Figure 1. Cells treated 
with cholera toxin or pertussis toxin were preincubated with CT or PT 
for 4-5 h prior to addition of TGF-0, PMA or forskolin, incubated for 
2-3 h and then labeled with [^^S]methionine. The amount of acid-
insoluble [^®S]methionine incorporated by the cells was measured as 
described in Experimental Procedures. Each value is the average of 2 
to 14 experiments with two independent estimates for each experiment. 
The paired Students t-test was used for statistical analysis. The 
analysis was done by comparing the values from control samples with 
the values from each growth modulator treatment sample. A t-test 
for the forskolin/TGF-^- and forskolin/PWA-treated samples was done by 
was done by comparing those samples with the TGF-/3- and PMA-treated 
samples, respectively. A t-test for the cholera toxin/TGF-/9- and 
cholera toxin/PMA-treated samples was done by comparing those samples 
with the TGF-/8- or PMA-treated samples, respectively. The number in 
parentheses is the number of experiments.® 
®p < 0.005. 
^p < 0.01. 
°p < 0.05. 
 ^< 0.1. 
®Where there is no letter,the p value was > 0.1. 
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secreted levels of PAI-1. Unlike HT-1080 and WI-38 cells 
(8), these cells do not produce PAI-1 in response to the 
synthetic glucocorticoid dexamethasone (data not shown). 
We have shown that the protein that we identify as PAI-1 
that is secreted by these cells can be inmunoprecipitated 
with the antibody to bovine endothelial cell plasminogen 
activator inhibitor (9). In addition, all four of these 
cell lines secrete increased amounts of plasminogen 
activator inhibitor in response to TGF-/3 as visualized by 
reverse zymography (data not shown). Because reverse 
zymography is a semiquantitative assay, no quantitation was 
attempted but the differences were apparent. 
The Effect of PKC Down-regulation on TGF-# Induction of PAI-1 
PMA has been identified as a ligand for protein kinase 
C. To determine whether protein kinase C was involved in 
the TGF-/S signalling pathway, we treated CCL64 cells with 
high concentrations of PMA (100 ng/ml) for 48 h and then 
challenged them with TGF-/S or PMA. The results (Figure 2) 
show that EGF and TGF-/9 but not PMA were able to induce 
PAI-1 in cells that had been preincubated with PMA. 
Figure 2. The effect of long term exposure to high 
concentrations of PMA on induction of PAI-l 
CCL64 cells were treated with 0.1% DMSO or 100 ng/ml 
PMA and 0.1% DMSO for 48 h. At the end of this 
preincubation period the medium was removed and replaced 
with [^^S]methionine labeling medium with 0.2% calf serum 
and the indicated growth modulators: 5 ng/ml EGF (with 
0.005% BSA) , 1 U/ml pTGF-/3 (with 2 mM acetic acid), EGF and 
pTGF-/3 in combination or 10 ng/ml PMA (with 0.1% DMSO). 
The control treatment consisted of the carriers for each 
growth modulator. The carriers were 2 mM acetic acid, 
0.005% BSA, and 0.1% DMSO final concentration. The cells 
were labeled with [^®S]methionine for 6 h. The cell densi­
ties varied between 1.3 x 10^ to 2.6 x 10^ cells/ well. 
Samples of medium were run on 7.5-15% SDS-PAGE as described 
under "Experimental Procedures." PAI-1 is marked with an 
arrow. -, control; E, epidermal growth factor; T, porcine 
TGF-/3; TE, TGF-/3 and EGF; P, phorbol myristate acetate. 
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cAMP Regulation of PAI-1 Gene Expression 
To examine the influence of cAMP on the induction of 
PAI-1, we treated AKR-2B, BSC-1, CCL64 and NRK cells with 
various factors that can alter the concentration of cAMP 
within the cell. Forskolin, a direct activator of 
adenylate cyclase, added simultaneously with TGF-/3 and PMA, 
blocked or significantly lowered the TGF-#- and PMA-induced 
expression of PAI-1 as shown in Figure 3A for CCL64 cells 
and 3B for NRK cells. Forskolin also lowered the basal 
level of expression of PAI-1 in all the cell lines except 
CCL64 which often had basal PAI-1 levels too low to 
measure. The results for basal level of secretion of PAI-1 
by CCL64 cells in the presence and absence of forskolin 
were sufficiently variable that the differences were not 
significant to the p < 0.1 level. Significant effects were 
observed; forskolin reduced both basal and induced PAI-1 
levels by 30-100%. Cholera toxin, also lowered the TGF-^S-
induced expression of PAI-1 (Table 1). 
In NRK clone 49F cells, forskolin strongly inhibited 
the induction of a 62/65 kDa protein that was induced 
specifically by PMA (Figure 3B). In contrast to PAI-1, the 
basal level of the 62/65 kDa protein was not significantly 
lowered by forskolin. PMA induced this protein by an 
average of 32-fold compared with control cells after a 6 h 
Figure 3A. The effect of forskolin on induction of 
secreted proteins 
CCL64 cells were treated with 50 /nM forskolin at the 
same time as the indicated growth regulators were added. 
The control treatment consisted of all the carrier 
solutions of the individual growth modulators (2raM acetic 
acid and 0.1% DMSO). The cells were labeled with 
[^^S]methionine 2.5 h later in the presence of the same 
factors that had been present in the preincubation. The 
labeled proteins were resolved on 7.5-15% SDS-PAGE. PAI-1 
is marked with an arrow. - , control; T, porcine TGF-/3; P, 
phorbol myristate acetate; Forsk, forskolin. 
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Figure 3B. The effect of forskolin on induction of 
secreted proteins 
NRK cells were treated with 50 fiK forskolin at the 
same time as the indicated growth regulators were added. 
The control treatment consisted of all the carrier 
solutions of the individual growth modulators (2mM acetic 
acid and 0.1% DMSO). The cells were labeled with 
[^^S]methionine 2.5 h later in the presence of the same 
factors that had been present in the preincubation. The 
labeled proteins were resolved on 7.5-15% SDS-PAGE. PAI-1 
is marked with an arrow. - , control; T, porcine TGF-^; P, 
phorbol myristate acetate; Forsk, forskolin. 
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incubation. This protein was not induced by TGF-)8. 
Forskolin lowered the PMA- induced secreted levels of this 
62/65 protein by greater than 80% (Table 1). 
Figure 4 shows that both basal and TGF-j8-induced PAI-1 
mRNA levels in NRK cells are reduced after treatment with 
either forskolin or cholera toxin by amounts consistent 
with the reductions in level of PAI-1 secreted protein. 
TGF-)S induced PAI-1 mRNA 4.8-fold, while forskolin and 
cholera toxin reduced PAI-1 basal mRNA levels to 40% of 
control levels. 
The effects of forskolin and cholera toxin are not 
generally inhibitory for gene expression. For example, 
forskolin and cholera toxin both induced the 38 kDa major 
excreted protein (MEP, procathepsin L ,(22)) in AKR-2B and 
NRK cells (Figure 1, Figure 3B). MEP is induced by PMA 25-
fold (n=6 experiments), 7-fold by cholera toxin (n=2 
experiments) and 4- fold by forskolin (n=2 experiments) 
compared with control levels. Addition of PMA with either 
cholera toxin or forskolin results in a synergistic 
increase in MEP levels. PMA plus forskolin results in a 
40-fold increase in MEP levels while PMA plus cholera toxin 
results in a 64-fold increase compared with control levels. 
Treatment of cells for 6 to 7 h with forskolin, cholera 
Figure 4. The effect of agents that elevate intracellular 
cAMP on the induction of PAI-1 mRNA levels 
NRK (clone 49F) cells were treated with 100 ng/ml 
cholera toxin for 4 h prior to the growth modulator 
addition or with 50 /iM forskolin at the time of growth 
modulator addition. Control- treated cells received the 
carrier components of the growth modulators used within 
this experiment (2 mM acetic acid, 1% HgO and 0.1%DMSO). 
Total RNA was isolated as described in "Experimental 
Procedures" 8.5 h after growth modulator addition. Rat 
PAI-1 cDNA was labeled with [^^P]dCTP by the random hexamer 
priming method as described by the Amersham manufacturer. 
-, control; T, porcine TGF-/9, FORSK, forskolin, CT, cholera 
toxin. 
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toxin, or dibutyryl cAMP had no effect on the rate of 
protein synthesis or on the number of cells on the dish. 
The Effect of Pertussis Toxin on TGF-j8-effected Signal 
Transduction 
Pertussis toxin, which can ADP-ribosylate the a-
subunit of G^-like G-proteins that have been implicated as 
modulators of the TGF-/3 signal, had little or no effect on 
TGF-/3- or PMA- induced expression of any secreted protein 
under these conditions. However, pertussis toxin did 
inhibit DNA synthesis in BSC-1 and AKR-2B cells (Table 2). 
Analysis of Transcription Rates by Nuclear Run-on 
To determine the relative changes in transcriptional 
activity in response to TGF-/3, PMA and forskolin, nuclear 
run-on transcription assays were performed to measure 
several gene activities including those of the PAI-1, a-
actin, fibronectin, and MEP genes. Quantitation of the 
PAI-1 signal (Figure 5) by densitometric analysis showed 
that PAI-1 gene activity in NRK clone 49F cells was 
significantly increased over the control levels in TGF-/3 
and PMA-treated cells. Forskolin lowered the TGF-/3 
induction of PAI-1 transcription by a range of 60-80% in 
TABLE 2. The effect of growth modulators on incorporation 
of [H]thymidine in AKR-2B, BSC-1, CCL64 
and NRK cells 
Cell line CCL64 BSC-1 AKR-2B NRK 
Addition (Fold over Control) 
Control 1.0 (8) 1.0 (5) 1.0 (5) 1.0 (5) 
TGF-f 0.034a(8) 0.63b(5) 1.1 (5) 1.4 (5) 
PMA 1.2 (8) 0.I3(5) 3.3^(5) 0.8 (5) 
Forsk 0.02^(3) 0.3 (1) 0.4 (1) 
Forsk + TGF-jS 0.013(3) 0.4 (1) 0.3 (1) 
Forsk + PMA 0.04^(3) 0.0 (1) 0.3 (1) 
Pertussis toxin 1.2 (3) 0.5°(2) 0.83(2) 2.1 (1) 
PT + TGF-/3 0.033(3) 0.33(2) 0.3°(2) 2.7 (1) 
PT + PMA 1.03 (3) 0.I3(2) 3.3^(2) 1.7 (1) 
Cholera toxin 0.033(3) 0.5 (2) 0.3°(2) 0.1 (1) 
CT + TGF-/3 0.023(3) 0.3 (2) 0.2 (2) 0.4 (1) 
CT + PMA 0.133(3) 0.1 (2) 0.5 (2) 0.4 (1) 
TGF-# (1 Unit/ml), PMA (10 ng/ml), forskolin (50 mM), 
pertussis toxin (100 ng/ml), or cholera toxin (100 ng/ml) were 
added to cells which had been plated on cover slips 20-24 h 
before labeling with [^H]thymidine for 4-5 h in the presence of 

Cholera toxin 
CT + PMA 
CT + TGF-j8 
0.03®(3) 0.5 (2) 0.3®(2) 0.1 (1) 
0.023(3) 0.3 (2) 0.2 (2) 0.4 (1) 
0.13*(3) 0.1 (2) 0.5 (2) 0.4 (1) 
TGF-p (1 Unit/ml), PMA (10 ng/ml), forskolin (50 fM), 
pertussis toxin (100 ng/ml), or cholera toxin (100 ng/ml) were 
added to cells which had been plated on cover slips 20-24 h 
before labeling with [^H]thymidine for 4-5 h in the presence of 
the additions indicated. Cover slips were fixed and 
[^H]thymidine incorporation was measured by liquid scintillation 
counting. Each value is the average of 1-8 experiments with two 
independent estimates for each experiment. The paired Student's 
t-test was used for statistical analysis. The analysis was done 
by comparing the values from control samples with the values for 
each growth modulator-treated sample. The number in parentheses 
represents the number of experiments.® 
®p < 0.005. 
p^ < 0.01. 
® p  <  0 . 0 5 .  
^ < 0.1. 
®Where there is no letter, the p value was > 0.1. 

Figure 5. Transcriptional analysis of PAI-1 by nuclear run-on 
NRK cells were treated for 2 h with 1 U/ml GI/TGF-# or 
10 ng/ml PMA with or without 50 /xM forskolin. The control-
treated cells received the carriers for the individual 
growth modulator treatments including 2 mM acetic acid and 
0.1% DMSO. Nuclei were isolated and used for in vitro 
transcription/nuclear run-on as described in "Experimental 
Procedures." 125 /iCi [^^P]UTP was used with each set of 
nuclei. After hybridization for 4 d at 42 C, the strips 
containing the indicated cDNAs were exposed to X-Ray film 
for 2 d. Plasmids containing the indicated cDNA had been 
linearized with appropriate restriction enzymes. rPAI-1, 2 
jLtg rat PAI-1 cDNA (17) , act in, 2 /ig mouse act in; FN, 2 jug 
mouse fibronectin; pBR322, 2 nq pBR322; and MEP, 2 jug 
cathepsin L. -, control T, GI/TGF-/3, P, PMA, forsk, 
forskolin. 
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NRK cells (n=3 experiments). Analysis of the basal level 
of transcriptional activity of the PAI-1 gene was not 
possible as it was below the level of detection in this 
assay. 
The TGF-iS Receptor in TGF-p and PMA Signal Transduction 
To determine whether the TGF-#-receptor was necessary 
for induction of PAI-1, MLEM and RIB cells (two cell lines 
lacking Type 1 TGF-)8-receptors) were treated with GI/TGF-/3 
or PMA for 2 h and then labelled with [^^S]methionine for 5 
h in the presence of the same factors. Samples of medium 
from cells treated with TGF-/3 or PMA were 
immunoprecipitated with antibody raised against purified 
bovine endothelial cell plasminogen activator inhibitor. 
GI/TGF-/3 did not induce PAI-1 in either mutant. By 
contrast, PMA induced of PAI-1 in both MLEM and RIB cells 
to levels approximately equivalent to PMA-induced PAI-1 
levels from the CCL 64 cell line (Figure 6). 
The Effect of TGF-/3, PMA and Inducers of cAMP on DNA Synthesis 
To examine the effects of the intracellular cAMP level 
on TGF-j8- or PMA-induced changes on the rate DNA synthesis, 
we treated AKR-2B, BSC-1, CCL64 and NRK cells with TGF-/3 or 
Figure 6. The effect of GI/TCF-jS and PMA on induction of 
PAI-1 in CCL64, MLEM and RIB cells 
CCL64, MLEM and RIB cells were plated in DMEM with 1% 
calf serum. Twenty-four h later, the medium was changed to 
fresh DMEM with 0.5% calf serum. Thirty-six h later, 
GI/TGF-0 (T) or PMA (P) was added. The control-treated 
cells received the carrier for each individual growth 
modulator treatment (2 mM acetic acid and 0.1% DMSO). The 
cells were incubated for 2 h, then the medium was replaced 
with [^^S]methionine medium with the appropriate growth 
modulator and the cells were labeled for 5 h. Medium from 
each treatment was immunoprecipitated with anti-PAI-1 
antibody. The original media and the immunoprecipitates 
were resolved by SDS gel electrophoresis. PAI-1 is noted 
with the arrow. -, control; T, GI/TGF-/3; P, PMA; MED, 
original medium; IP, immunoprecipitates. 
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PMA alone and in combination with forskolin, cholera toxin, 
and dibutyryl cAMP. Forskolin and cholera toxin 
significantly lowered the basal rate of DNA synthesis in 
all four cell lines as measured by incorporation of 
[^H]thymidine. The basal rate of DNA synthesis was 
decreased by about 97% in CCL64 cells, 70% in BSC-1 cells 
and 60% in AKR-2B cells after treatment by forskolin. 
Similar decreases were observed in the rate of 
[^H]thymidine incorporated by TGF-#- and PMA-treated cells 
(Table 2). 
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DISCUSSION 
Previously, we showed that TGF-/9 and PMA induced PAI-1 
expression in CCL64 near term mink lung epithelial, and 
BSC-1 African green monkey kidney epithelial cells. We 
also found that TGF-/3 and PMA induced PAI-1 in NRK normal 
rat kidney fibroblast cells. By contrast, TGF-/3 induced 
PAI-1 in AKR-2B mouse embryo fibroblast cells but PMA did 
not (9). PAI-1 levels were induced by TGF-j8 in every cell 
line that we examined. 
Others have shown that TGF-/9 induced rapid increases 
in the level of PAI-1 mRNA within one and five hours of 
treatment, depending on the cell line (28). Inhibitors of 
protein synthesis such as cycloheximide had no effect on 
the ability of TGF-/3 to induce PAI-1 and could themselves 
increase the cellular level of PAI-1 mRNA (29). These 
results showed that the induction of PAI-1 by TGF-jS and PMA 
did not depend on protein synthesis (28,30). PAI-1 
expression could also be induced in some cells by basic 
fibroblast growth factor (FGF (31)), lipopolysaccharide 
(29,32), interleukin-1 (33,34), glucocorticoids (35), tumor 
necrosis factor-a (29), and EGF (36). We have not seen 
induction of PAI-1 in any of the cell lines discussed in 
this report by FGF or the synthetic glucocorticoid 
dexamethasone. EGF only induced PAI-1 in CCL64 mink lung 
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cells. The induction of PAI-1 by EGF was synergistic with 
the induction by TGF-/3 in CCL64 cells (9) . PAI-1 mRNA has 
a relatively short half-life (2.2 to 3 h) (34). Therefore, 
regulation of PAI-1 mRNA levels could be achieved by 
regulating PAI-1 mRNA degradation or transcription. We 
have found that TGF-/5 and PMA increased the number of 
transcripts for PAI-1 in NRK and BSC-1 cells. Similar 
results have been reported for human endothelial and lung 
WI38 cells (28). 
PMA, as well as retinoids and TGF-#, in the 
appropriate cell system, can inhibit growth of cells and/or 
induce differentiation (37). We and others have 
demonstrated that phorbol l2-myristate 13-acetate (PMA), 
presumably by activating protein kinase C, can induce PAI-1 
(9,12). TGF-^S has been reported to activate protein kinase 
C in microvessels from brain (38). Therefore, we 
hypothesized that TGF-/3 might induce PAI-1 by activating 
the PKC second messenger signal transduction pathway. If 
this were so, then down-regulation of PKC activity should 
have resulted in diminished responsiveness of PAI-1 to TGF-
j9 induction. Chronic exposure to PMA for 24 h down-
regulates PKC levels in most cell types, including 3T3 
fibroblasts (39), although cells down-regulate PKC variably 
(40). We found that protein kinase C is not an obligatory 
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step in the mechanism by which TGF-jS signals the induction 
of PAI-1. Down-regulation of PKC by prolonged exposure to 
high levels of PMA had no effect on the ability of TGF-jS to 
induce PAI-1 in CCI 64 cells whereas it lowered the PMA-
induced level of PAI-1 production below the control level. 
The protein kinase inhibitor H7 also lowered PMA-induced 
levels of PAI-1, but not TGF-/8-induced production of PAI-1 
(data not shown). Therefore, while induction of PAI-1 by 
PMA is PKC-dependent, TCF-jS induction of PAI-1 does not 
depend on activation of PKC. 
Our experiments clearly show that agents that increase 
the intracellular concentration of cAMP inhibit basal and 
TGF-#- and PMA-induced levels of PAI-1 protein and mRNA 
expression. Santell and Levin (13) demonstrated that 
increased cAMP levels can potentiate the phorbol ester-
induced release of tissue plasminogen activator (tPA) and 
prevent the PMA-induced secretion of PAI-1 from human 
endothelial cells. Daniel et al. demonstrated that agents 
that increase intracellular cAMP lower the basal sis level 
and block the induction of c-sis by thrombin and TGF-j8 in 
human endothelial cells (14). We show that agents that 
increase intracellular cAMP specifically lower the basal 
and TGF-/3-induced level of expression of PAI-1 and PAI-1 
mRNA. Our results support the finding that increased cAMP 
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reduces basal expression of PAI-1 but our results do not 
support the finding that increased intracellular cAHP 
prevents the PMA- induced response. Our results also show 
that agents that elevate cAMP lower both basal and TGF-j9 
induced mRNA levels and the TGF-/9~induced PAI-1 gene 
activity as measured by nuclear run-on in NRK clone 49 F 
cells. 
CAMP positively regulates the mRNA levels of genes 
such as preproenkephalin (41), somatostatin (42), chorionic 
gonadotropin (43) and phosphoenolpyruvate carboxykinase 
(44) at least partly at the level of transcription. cAMP 
negatively regulates transcription of EGF-induced 
transin/stromelysin. Transin/stromelysin is a 
metalloprotease overexpressed in carcinomas that have a 
high tendency for metastasis (45). The report by Daniel et 
al. suggests that the TGF-/3 and PMA signal transduction 
pathways in human endothelial cells for induction of c-sis 
are different because inducers of cAMP attenuated the 
response to TGF-jS and had no effect on the PMA induction of 
c- cis (14). This observation differs from our results. 
We found that addition of forskolin, which raises 
intracellular cAMP by directly activating adenylate cyclase 
(46), decreased both TGF- /8- and PMA-induced PAI-1 
expression in BSC-1, CCL64 and NRK cells. 
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The human PAI-1 gene has been sequenced and several 
regulatory sequences within the 5'-upstream region of the 
gene have been identified. The human PAI-1 gene has a 
glucocorticoid response element (TGT(T or C)CT or 
TGT(Py)CT) which is present at -299 in the anti-sense 
orientation (AGGACA) of the PAI-1 promoter, and there is no 
SP-1 site (47). NF-l/CTF was shown to mediate TGF-#-
induced enhancement of promoter activity for the alpha2(I) 
collagen gene (48). A possible AP-1 site has been reported 
in the 5'-upstream sequence of the human PAI-1 gene, along 
with a glucocorticoid enhancer element TGCCTCAG (49), 
although there is no report of an NF-1 site on the PAI-1 
promoter and no negative regulatory element has been 
identified. 
The cis-actina element that mediates cellular 
responses to cAMP, called the cAMP responsive element 
(CRE), and the cis- acting element that mediates induction 
by phorbol ester tumor promoters such as TPA/PMA, called 
the TPA responsive element (TRE) or AP-1 site, have very 
similar consensus sequences (5'- TGACGTCA-3' for CRE and 
5'-TGA(G/C)TCA-3' for TRE). It appears that these 
responsive sites are recognized by several proteins and 
that their activities are affected by surrounding 
sequences. There are also cell-specific differences in 
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the response of specific genes to cAMP and TPA (50,51,52). 
In addition to the similarity of consensus sequences, the 
protein transcription factors for the two sites (CREB and 
AP-1) also have similar molecular masses (43 kDa for CREB 
(53)) and 44-47 kDa for AP-1 (54,55). cDNA sequences for 
CREB and AP-1 have been reported (56). AP-l and CREB may 
be members of a gene family because there is also 
immunological cross-reactivity between anti-iun antibodies 
and purified CREB (57). Portions of the reported CREB 
protein sequence are very similar to an equivalent portion 
of the iun/AP-1 sequence, the DNA-binding domain portion of 
iun/AP-1. 
The inhibition of PAI expression by cAMP is seen in 
cells from both epithelial and fibroblast origin and in 
cells from both rodent and monkey species. The extent of 
the inhibition varies between cell lines. These changes in 
PAI-1 protein and mRNA expression parallel changes in the 
rate of PAI-1 gene transcription. It has been reported by 
Sawdey et al. that the tj^_2 of PAI-1 mRNA in bovine aortic 
endothelial cells is about 2.2 h (29). We have obtained 
similar results with BSC-1 cells (unpublished data of author). 
While CCL64 cells have three membrane-associated TCF-jS 
binding proteins (58,59), the type I receptor is probably 
the mediator of TGF-/3-induct ion of fibronectin and 
64 
Inhibition of proliferation. This was shown with 
mutagenized CCL64 cells selected for resistance to TGF-#. 
In these TGF-/3-resistant cells TGF-/3 does not induce 
fibronectin or inhibit DNA synthesis and the type I 
receptor is not expressed. These cells are recessive 
mutants (20, and Frederick T. Boyd, Cell Biology and 
Genetics Program, Sloan-Kettering Cancer Center, New York, 
NY, personal communication). Another TGF-^-insensitive 
mutant CCL64 cell line cell which does not respond to the 
growth inhibitory action of TGF-# with changes in 
morphology or with increased fibronectin synthesis, also 
secreted less of a 48 kDa protein in response to TGF-jS. 
This protein was postulated to be PAI-1 (19). Our results 
demonstrate that these mutant cells also do not produce 
PAI-1 in response to TGF-^S. However, both mutant cell 
lines, which do not express the type I TGF-/S receptor, can 
still be induced to synthesize and secrete PAI-1 by PMA. 
These data show that the activation of the type 1 TGF-/9 
receptor is necessary for TGF-/8 induction of PAI-1 and that 
induction of PAI-1 by PMA is independent of the TGF-/3-
receptor. 
We have also identified a 62/65 kDa protein doublet 
that is induced by PMA and not by TGF-/3 in NRK cells. 
Although this doublet is the same size as osteonectin 
65 
(SPARC), a 62,000 Mj. phosphoprotein secreted from rodent 
cells for which there is an association to transformation, 
a polyclonal antibody to osteonectin did not 
immunoprecipitate the PMA-induced 62/65 kDa protein (60). 
Kinetics of induction of the 62/65 kDa doublet protein by 
EGF, plus TGF-jS, were similar to those for a 69 kDa protein 
induced by EGF plus TGF-jS reported by Laverdure et al. (61) 
with maximal induction occurring after 24 h of treatment. 
PMA maximally induces 62/65 doublet protein by 5 to 6 h 
after initial treatment (data not shown). In contrast to 
PAI-1, the basal level of the 62/65 kDa protein induced by 
PMA was not lowered in response to forskolin, while 
induction of the 62/65 kDa protein was lowered by forskolin 
to 20% of the value for cells treated with PMA alone. 
Thus, regulation of expression of this gene by cAMP is not 
accomplished by a general lowering of the basal expression 
of the gene as it appears to be for PAI-1. 
Cholera toxin and forskolin, agents that increase the 
intracellular level of cAMP, inhibit PAI-1 expression and 
DNA synthesis in all four cell lines. Thus, increasing 
levels of cAMP negatively regulate the expression of PAI-1 
and DNA synthesis by decreasing the basal rates of these 
activities. 
In contrast to their effects on induction of PAI-1 and 
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the 62/65 kDa protein, cholera toxin, and forskolin induce 
synthesis and secretion of MEP in AKR-2B cells (Figure 1, 
Table 1). Thus, the regulation of gene expression by cAMP 
elevating agents is gene specific and is not the result of 
general lowering of all gene activities. PMA and cholera 
toxin induced MEP in an synergistic manner, indicating that 
they might activate separate signal transduction pathways 
to increase the rate of gene expression. 
Work by Murthy et al. (15) and Howe and Leof (16) 
suggests that the TGF-/S-induced mitogenesis of AKR-2B cells 
could be controlled by a GTP-binding protein. This 
conclusion was based on the observation that pertussis 
toxin, which uncouples certain receptor-GTP-binding protein 
complexes through ADP-ribosylation of the a-subunit (63) of 
a G^-like protein (64) inhibited the effect of TGE-^S on DNA 
synthesis. However, we found that pertussis toxin had 
little or no effect on the abilities of TGF- jS or PMA to 
induce PAI-1 in any of the cell lines studied (data not 
shown). Murthy et al (15) and Howe and Leof (16) used TGF-
from human platelets in their experiments. Although 
TGF-#2 was not tested by Murthy, et al., Howe and Leof 
showed that TGF- P2 did not stimulate binding of GTP to 
AKR-2B membranes while TGF-/S1 stimulated GTP binding by 
greater than 60%. TGF-j82 wr*3 not assayed further by Howe 
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and Leof. In the experiments reported here we used TGF-/9 
purified from porcine platelets (pTGF-/3) and from the 
medium of African green monkey epithelial cells (GI/TGF-f, 
64,65). The porcine TGF-jS preparation that we used was a 
mixture of TGF-/31 and TGF-/92. TGF-/32 makes up greater than 
90% of this TGF-/3 preparation (66). Thus it is possible 
that the TGF-/31, but not the TGF-/32 signal pathway is 
regulated by a G-protein. We have also demonstrated that 
the TGF-/32 effect on PAI-1 is mediated by the type I TGF-^S 
receptors. This suggests that G^ may mediate the effect of 
TGF- jSl and TGF-j92 through the type II or III receptors 
rather than the type I receptor. 
We also observed no mitogenic effect of TGF-/32 on AKR-
2B fibroblasts and pertussis toxin itself inhibited DNA 
synthesis about 25% in growing cells in low calf serum. 
TGF-# stimulates DNA synthesis in quiescent AKR-2B cells 
but with a delayed replication time (67). The stimulation 
is through an indirect mechanism via induction of the c-sis 
gene followed by the autocrine action of PDGF (68). Howe 
and Leof (16) showed that TGF-jSl induced binding of GTP by 
AKR-2B membranes in a dose dependent manner and increased 
the number of GTP-binding sites by 30%. TGF-#1 also 
increased GTPase activity. EGF, platelet derived growth 
factor (PDGF), insulin and TGF-/32 had no effect on GTP 
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binding. Pretreatment of membranes with pertussis toxin 
inhibited TGF-/31-induced OTP binding and GTPase activity. 
Murthy et al. showed both lowered GTP binding and lowered 
GTPase activity after pertussis toxin pretreatment and 
stimulation by TGF-^1. However, cholera toxin could not 
prevent the TGF-^l- induced mitogenesis of AKR-2B cells 
(15). 
G-proteins may be involved in growth factor-mediated 
cell proliferation in several fibroblast cell lines. 
Pretreatment with pertussis toxin prevented stimulation of 
DNA synthesis by EGF or PDGF in mouse fibroblasts. 
However, pertussis toxin added 7 h after growth factor 
treatment can not prevent mitosis (69,70). Thus, while a 
Gj^-like protein may be involved in the events leading to 
mitogenesis and eventual proliferation of quiescent AKR-2B 
cells mediated by sis, there is no evidence in our data to 
suggest that a Gj^-like protein is involved in TGF-j8-
induced synthesis of PAI-1 or TGF-i8-induced inhibition of 
growth. Further experiments are being conducted to compare 
the effect of pertussis toxin on TGF-#1 and TGF-/32 mediated 
induction of PAI-1. 
In summary, the results reported here have shown that 
TGF-^S and PMA both induce PAI-1 but TGF-jS does not depend 
on a protein kinase C signal transduction pathway. 
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Induction of PAI-1 by TGF-/3 is mediated by the type I TGF-/3 
receptor. Compounds that increase the intracellular 
concentration of cAMP lower both the basal and TGF-/32-
induced secreted levels of PAI-1 coordinately through a 
decrease in the rate of PAI-1 transcription. Inducers of 
cAHP had no effect on the ability of TGF-/3 to induce PAI-1 
or to affect DNA synthesis. Also pertussis toxin does not 
inhibit TGF-jS-induced PAI-1 expression. Therefore, for 
PAI-1 and presumably for genes that regulate the rate of 
initiation of DNA synthesis, cAMP regulates the level of 
gene activity and does not regulate the TGF-)8 signal 
transduction pathway(s). The TGF- ^ -regulated PAI-1 gene 
expression is also regulated through the type I TGF-/3 
receptor by a pertussis toxin-insensitive pathway that is 
not expected to involve G^. 
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SECTION II. 
TGF-/3 AND RETINOID REGULATION OF EPITHELIAL 
CELL PROTEIN EXPRESSION 
76 
ABSTRACT 
Transforming growth factor p (TGF-/3) and retinoids 
have many similar effects on cellular processes such as 
differentiation, proliferation and gene expression. We 
report here that TGF-# and two retinoids (retinoic acid and 
retinoyl /3- glucuronide) induce near term mink lung epithe­
lial (CCL64) cells to synthesize and secrete a 73 kDa 
protein that we have called Inhibitor-induced protein, 
73,000 (IIP73) . IIP73 can be induced by TGF-/3 and retinoic 
acid up to 170-fold compared with control levels and the 
induction is maximal by 24-32 h after treatment. The 
induction of IIP73 by TGF-/3 and retinoic acid can be 
blocked by both actinomycin D and cycloheximide which 
indicates the need for both new mRNA and protein synthesis. 
The effects of TGF-/3 and retinoic acid on induction of 
IIP73 are additive. This indicates that TGF-# and retinoic 
acid act through different signal transduction pathways. 
Down-regulation of protein kinase C had no effect on the 
TGF-# and retinoic acid induced synthesis and secretion of 
IIP73. In contrast to the regulation of PAI-1 by TGF-/3, 
agents which increase intracellular cAMP such as forskolin 
or dibutyrly cAMP have no effect on the basal, TGF-/3- or 
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retinoic acid-induced levels of IIP73 expression. The tumor 
promoter, phorbol 12-myristate 13-acetate (PMA) also does 
not induce IIP73 whereas it does induce PAI-1. In CCL64 
cell mutants that lack the type I TGF-# receptor, retinoic 
acid induced IIP73 whereas TGF-jS did not. Therefore, IIP73 
expression is regulated differently than PAI-1 in CCL64 
cells and is regulated differently by retinoic acid than by 
TGF-jS. 
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INTRODUCTION 
Retinoids such as retinoic acid and other vitamin A 
derivatives are regulators of growth and differentiation 
which are capable of suppressing the transformed phenotype 
in many types of cancer cells. Retinoids are used as 
treatments for certain skin diseases and in prevention of 
epithelial cell cancers (1,2). Recent cloning of retinoic 
acid receptors (3,4,5) on the basis of their similarity 
with the steroid hormone receptors has provided evidence 
for a molecular basis of action of retinoids at the nuclear 
level (6). Retinoids regulate the expression of the 
polypeptide growth factor type-2 transforming growth factor 
/3 (TGF-/9) (7), and of other genes, including some that 
encode proteins associated with the extracellular matrix 
( 8 ) .  
TGF-iS also induces cell differentiation (9). It can 
be a potent inducer (10) or inhibitor of cellular 
proliferation (11,12,13). TGF-jS also induces genes whose 
products are associated with the cellular matrix such as 
collagen (14), fibronectin (15), proteoglycans (16), 
protease nexin (17), and plasminogen activator inhibitor 
(18), and inhibits genes for proteases such as cathepsin L 
(19), transin (20), plasminogen activator (21), and 
collagenase (22). Retinoic acid can also induce collagen 
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(23), fibronectln (24), and proteoglycans (25) and affects 
plasminogen activator (26) and collagenase (27) in a cell 
line specific manner. 
TGF-/3 and retinoic acid can have similar effects on 
DNA synthesis, cellular differentiation processes, and 
expression of components of the extracellular matrix 
(8,22). In this paper we report that TGF-/S and retinoic 
acid, and all-trans-retinoyl /9- glucuronide (28), also 
share the ability to induce synthesis and secretion of a 
73,000 Mj. protein that we call Inhibitor-induced protein, 
73,000 (IIP73). The induction of IIP73 by TGF-jS and 
retinoic acid is mediated through different signal 
transduction pathways and depends on mRNA and protein 
synthesis. The regulation of IIP73 by retinoic acid and 
TGF-/3 is not correlated with the ability of these growth 
modulators to regulate DNA synthesis in monolayer cultures. 
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MATERIALS AND METHODS 
PMA was from either Sigma or CCR, Inc. Bedford, Mass. 
4-0- methyl PMA was from CCR. pTGF-/3 was purified from 
porcine plasma by the method of Assoian et al. (29). 
GI/TGF-/3 was a gift from Dr. Robert Holley (Salk 
Institute). Epidermal Growth Factor (EGF) was from 
Collaborative Research. All-trans- retinoic acid was from 
Sigma. Retinoyl /3-glucuronide was a gift from Dr. Arun 
Barua (Iowa State University, Ames, Iowa). BSA, forskolin, 
thrombin, butyric acid, dibutyryl cAMP, cholera toxin, and 
pertussis toxin were purchased from Sigma. X-Ray film 
(XAR-5) was from Kodak. Radioisotopes were from New England 
Nuclear. All other chemicals and reagents were from Fisher 
Scientific or Sigma. 
Cell Culture and Cell lines 
All cells were cultured in Dulbecco-Vogt's modified 
Eagle's medium (DMEM), containing 0.45% glucose and no 
sodium pyruvate (Gibco), with 5-10% calf serum. Ten 
units/ml penicillin and 10 ng/ml streptomycin were included 
in all growth media. The stock cell cultures were grown as 
monolayers on plastic tissue culture dishes, at 37°C, in a 
water-saturated atmosphere, with 10% CO2 in air. CCL64 
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cells were from the American Type Culture Collection, the 
mink lung epithelial mutant (MLEM) cell line (30) was from 
Dr. Phillip Howe (Vanderbilt University, Nashville, TN), 
and the RIB, TGF-iS type-I receptor-minus cell line (31) was 
from Frederick T. Boyd and Dr. Joan Massagué, (Sloan 
Kettering Cancer Center, New York, NY). 
Labeling with [^®S]methionine 
The [^®S]methionine metabolic labeling method is 
described fully in a previous publications (18,32). In 
brief, cells were suspended in DMEM containing 0.2 to 1.0% 
calf serum and plated in 24-well tissue culture dishes. 
One to two days after the cells had attached to the dish, 
the medium was removed and fresh DMEM with 0.2%-0.5% calf 
serum was added. About 24 h later, additions were made and 
the cells were labeled with [^®S]methionine after the 
indicated incubation times. 
SDS-Polyacrylamide Gel Electrophoresis 
SDS-polyacrylamide gel electrophoresis, fluorography 
and densitometric measurement of [^®S]methionine in the 
protein bands were performed as previously described 
(18,33). The results from densitometer scans were 
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normalized to the rate of [^]methionine incorporation 
into cellular proteins by dividing the value of the area 
under the peak by the amount of acid- insoluble, 
[3®S]methionine radioactivity in the Nonidet P-40 soluble 
fraction of the cell preparation. 
[^H]thymidine Incorporation and Labeling Index 
Rates of DNA synthesis were estimated by incorporation 
of [^H]thymidine over a 4 h period. Cover slips with 
[^H]thymidine-labeled cells were prepared as previously 
described and [^H]thymidine incorporation into DNA was 
guantitated by liquid scintillation counting and by 
determining the labeling index (18). 
83 
RESULTS 
Characteristics of Growth Modulator Induction of IIP73. 
Growth factors have different effects on the induction 
of IIP73 in CCL64 cells (Figure 1). TGF-#, retinoic acid 
and retinoyl-/3-glucuronide, a water soluble retinoid 
derivative, are all potent inducers of IIP73 in CCL64 
cells. In the experiment shown, IIP73 levels from CCL64 
cells were induced greater than 9-fold over control levels 
after a 24 h incubation with TGF-jS and 16-fold after a 24 h 
treatment by retinoic acid. In three of four experiments 
we found that TGF-/3 induced IIP73 10- to 30- fold and that 
retinoic acid induced IIP73 11- to 15-fold compared with 
control levels after 24 h incubation. In the fourth 
experiment, IIP73 was induced by more than 170-fold by TGF-
/3 and by more than 138-fold by retinoic acid. The 
increases in TGFjS, retinoic acid and retinoyl-jS-glucuronide 
induced IIP73 were 3.3-, 2.9- and 3.4-fold vs control 
levels respectively after a 6 h treatment. EGF had no 
effect on IIP73 production and PMA lowered IIP73 production 
by CCL64 cells. When added in combination, TGF-/9 and 
retinoic acid had an additive effect on the secreted levels 
of IIP73 (Table 1). 
To determine whether IIP73 is N-glycosylated, CCL64 
Figure 1. The effect of TGF-/3, PMA and RA on the 
induction of secreted proteins in CCL64 cells 
CCL64 cells were plated in DHEH + 0.5% calf serum. 
Twenty- four h after plating the medium was changed to 
fresh DMEM with 0.5% calf serum and 24 h later 2 mM acetic 
acid, 0.1% Me2S0 and 0.1% EtOH with or without 1 U/ml 
GI/TGF-p, 10 ng/ml PMA or 10~®M retinoic acid. Twenty h 
later, the cells were labeled for 5 h with [^®S]methionine 
with the same factors present as during the preincubation. 
-, control; E, EGF; T, GI/TGF-/8; TE, GI/TGF-)S and EGF; P, 
PMA; RA, retinoic acid. The arrows show the positions of 
IIP73 and fibronectin (FN). 
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Table 1. The effect of TGF-/3, retinoic acid, and retinoyl 
/3-glucuronide on secreted levels of IIP73 by 
CCL64 cells 
IIP?3 area/cpm 
fold/control fold/control 
Addition 6 h inc 24 h inc 
control 1.0 (10) 1.0 (5) 
TGF-iS 3.27® (10) 59.75®(5) 
Retinoic acid 2.88° (10) 44.53®(4) 
TGF-/3 + RA 6.15® (10) nd 
Retinoyl jS-
glucuronide 
3.41° (4) nd 
TGF-/3 (1 Unit/ml), retinoic acid (10"®M), retinoyl /8-
glucuronide (10""®M) were added to CCL64 cells for 2 or 20 h 
as indicated and then were labeled with [^^S]methionine for 
4-5 h. IIP73 bands were scanned with a densitometer and 
the area under the peak was normalized to the acid 
insoluble (PNS) cpms. Each fold/control value is the mean 
of 4-10 experiments with two independent estimates for each 
experiment. The paired Students t-test was used for 
statistical analysis. The analysis was done by comparing 
the value from the control samples with values from TGF-p-, 

TGF-/3 (1 Unit/ml), retinoic acid (10~®M), retinoyl j8-
glucuronide (lO^^M) were added to CCL64 cells for 2 or 20 h 
as indicated and then were labeled with [^®S]methionine for 
4-5 h. IIP73 bands were scanned with a densitometer and 
the area under the peak was normalized to the acid 
insoluble (PNS) cpms. Each fold/control value is the mean 
of 4-10 experiments with two independent estimates for each 
experiment. The paired Students t-test was used for 
statistical analysis. The analysis was done by comparing 
the value from the control samples with values from TGF-j3-, 
retinoic acid- or retinoyl j8-glucuronide-treated samples. 
The number in parentheses is the number of experiments.® 
®p < 0.005. 
bp < 0.01. 
°p < 0.05. 
^ < 0.01. 
®Where there is no letter, the p value was > 0.1. 
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cells, that had been stimulated by TGF-p and retinoic acid, 
were treated with tunicamycin, a drug that inhibits N-
linked glycosylation at asparagine residues (Figure 2). 
Tunicamycin was present only during the labeling period. 
Tunicamycin inhibits protein synthesis approximately 50%. 
After normalizing the area of IIP73 to intracellular TCA 
precipitable cpms, there was no significant difference 
between the control IIP73 levels and tunicamycin-treated 
IIP73 levels. These results indicate that IIP73 is not N-
glycosylated. 
To determine whether TGF-p or retinoic are the primary 
inducers of IIP73, CCL64 cells were treated with either 
actinomycin D or DRB (inhibitors of RNA synthesis) or with 
cycloheximide (an inhibitor of protein synthesis). Cells 
were treated for 24 h with the inhibitors with or without 
TGF-jS or retinoic acid. Actinomycin D was present 
throughout while cycloheximide was not present during the 
labeling period. Actinomycin D, DRB, and cycloheximide 
prevented induction of IIP73 by either TGF-# or retinoic 
acid. These results indicated that TGF-/3 and retinoic acid 
are not primary inducers of IIP73 in CCL64 cells (Table 2). 
Figure 2. The effect of inhibition of N-glycosylation on 
TGF-/3 and retinoic acid inductions of IIP73 
CCL64 cells were plated in DMEM with 1.0% calf serum. 
Twenty-four h after plating, the medium was changed to DMEM 
with 0.5% calf serum and 24 h later 2 mM acetic acid, 0.1% 
EtOH and 0.1% Me2S0, with or without GI/TGF-/3 (1 Unit/ml), 
retinoic acid (10~®M), or tunicamycin (1.5 ng/ml during 
labeling only), was added. The control-treated cells 
received the carrier solutions for the growth modulators 
used in this experiment. Twenty-four h later the cells 
were labeled with [^^S]methionine for 4 h with the same 
factors present as during the preincubation. -, control; 
T, GI/TGF-0; RA, retinoic acid; TUN, tunicamycin. 
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Table 2. The effect of cycloheximide, actlnomycin D, or 
DRB on the induction of IIP73 by TGF-/S or 
retinoic acid 
— 
IIP73 
CHX 
area/cpm 
Act. D. DRB 
Expt. 1. 
control 1.0 0.0 o
 
o
 
1.0 
TGF-/3 10.7 0.0 0.0 2.5 
Ret. A. 14.6 0.0 0.0 1.1 
Expt. 2. 
control 1.0 0.0 0.0 
TGF-/3 17.0 2.1 0.0 
Ret. A. 106.0 0.0 0.0 
CCL64 cells were plated in DMEM with 0.5% calf serum. 
Twenty-four h after plating the cells were changed to fresh 
DMEM with 0.5% calf serum. Twenty-four h after the medium 
change the cells were treated for 20 h with 1 Unit/ml 
GI/TGF-/3 or 10~®M retinoic acid with or without 1 fig/ml 
cycloheximide (CHX), 1 /ig/ml actinomycin D (Act.D) or 50 /iM 
DRB. The cells were labelled for 4 h with [^®S]methionine 
for 4 h in the presence of all the factors present during 
the preincubation except cycloheximide. Because of the 
range between control values, two separate experiments are 
presented. 
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Concentration Dependence of Retlnoic Acid Induction of IIP73 
To determine the levels of retlnoic acid necessary to 
achieve maximum induction of IIP73 in CCL64 cells, we 
varied the concentration of retlnoic acid between 10""^ to 
10~^M and examined induction of IIP73. The results show 
that 10~®M retlnoic acid was the most effective of the 
concentrations tested in Inducing IIP73 (Figure 3). Levels 
of retlnoic acid higher than 10~®M were toxic to the cells 
and caused loss of cells from the dishes. 
Time courses of IIP73 Induction by TGF-j9 and Retlnoic Acid 
We compared the time courses of appearance of IIP73 
after treating CCL64 cells with TGF-# or retlnoic acid. 
The rate of production of IIP73 increased shortly after the 
addition of GI/TB or retlnoic acid, rose to a maximum by 22 
to 30 h after the initial treatment and then fell. The 
figure represents three experiments with duplicate samples. 
There was no significant difference in the rate of IIP73 
induction after treatment with either TGF-fi or retlnoic 
acid (Figure 4). 
Figure 3. Concentration dependence of retinoic acid 
induction of IIP73 
CCL64 cells were plated in DMEM with 1.0% calf serum. 
Twelve h after plating the medium was changed to fresh DMEM 
with 0.5% calf serum. Twenty-four h later, various 
concentrations of retinoic acid was added and 21 to 24 h 
later the cells were labeled with [^^S]methionine in the 
presence of the various retinoic acid concentrations for 4 
h. This figure represents the mean of three experiments 
with each treatment done in duplicate. 
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Figure 4. Time courses of GI/TGF-/3 or retinoid acid 
induction of IIP73 
CCL64 cells were plated in DMEM with 0.5% calf serum. 
Twenty-four h later, the medium was removed and replaced 
with fresh DMEM and 0.5% calf serum. Twenty-four h later, 
GI/TGF-p (1 Unit/ml) or lO^^M retinoic acid was added to 
some of the wells along with 2 mM acetic acid and 0.1% 
EtOH. The controls received 2 mM acetic acid and 0.1% 
EtOH. The cells were labeled for 4 h with [^^S]methionine-
labeled medium beginning 0-50 h after addition of GI/TGF-0 
or retinoic acid. The values for IIP73 were found by 
scanning the protein band with a densitometer and 
normalizing the area to the NP-40 soluble TCA precipitable 
CPM. The time courses represent the average of thre 
experiments with each time point for each treatment done in 
duplicate, x , control; +, with GI/TGF-jS ; a, with 10~^M 
retinoic acid. 
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Involvement of TGF-/3 in the Mechanism by which 
Retinoic Acid Induces IIP73 
CCL64 cells were treated with retinoic acid for 
varying times in order to examine the kinetics of the PAI-1 
induction vs the IIP?3 induction. Over the course of this 
13 h experiment, there was no induction of PAI-1 by 
retinoic acid while IIP73 was induced up to 30-fold over 
control levels. Plasminogen activator inhibitor (PAI-1) 
which is strongly induced within 6 h by TGF-/3, was not 
induced at any time over the time course by retinoic acid 
(Figure 5). 
Effect of GI/TGF-/3, PMA and Retinoic Acid on the 
Induction of Secreted Proteins in CCL64 and RIB cells 
To determine whether the TGF-/9 receptor is necessary 
for induction of IIP73, RIB mutant cells, which do not have 
type I TGF-#-receptor (31) were treated with GI/TGF-#, 
retinoic acid and PMA for 14 h and then labeled with 
[^^S]methionine for 5 h in the presence of the same 
factors. GI/TGF-/3 and PMA did not induce IIP73 in the 
mutants. By contrast, retinoic acid increased the rate of 
synthesis and secretion of IIP73 in RIB cells (Figure 6). 
The mink lung epithelial mutant (MLEM) cell line, which is 
Figure 5. Time course of retinoic acid induction of IIP73 
CCL64 cells were plated in DMEM with 0.5% calf serum. 
Forty-eight h after plating, the medium was changed to 
fresh DMEM with 0.5% calf serum. Twenty-four h later, 2 mM 
acetic acid and 0.1% EtOH, with or without 10~®M retinoic 
acid was added for the time indicated including labeling 
the cells with [^^S]methionine for 4 h with the same 
factors present as duri ig the preincubation. The control-
treated wells received the carrier solution for the 
retinoic acid, 0.1% EtOH. -, control; RA, retinoic acid. 
The number represents hours with retinoic acid. 
98a 
17.5-
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Figure 6. The effect of GI/TGF-/3, PMA and retinoic acid on 
the induction of secreted proteins in CCL64 and 
RIB cells 
CCL64 cells were plated in DMEM with 0.5% calf serum. 
Twenty-four h after plating the medium was changed to fresh 
DMEM with 0.5% calf serum and 24 h later 2mM HOAc, 0.1% 
EtOH, and 0.1% Me2S0, GI/TGF-/3, PMA or retinoic acid were 
added. Fifteen h later, the cells were labeled with 
[^^S]methionine for 4 h with the same factors present as 
during the preincubation. The control-treated cells 
received the carrier solution for the growth modulators 
used in this experiment. The cells treated with growth 
modulator received the carrier solution from the other 
growth modulators. -, control; T, GI/TGF-/3; P, phorbol 
myristate acetate; RA, retinoic acid. 
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also TGF-/3 non-responsive (30) did not respond to GI/TGF-/3 
and PMA with IIP73 induction but could be induced to 
synthesize and secrete IIP73 in response to retinoic acid 
(data not shown). Both RIB and MLEM cells could be induced 
to synthesize and secrete PAI-1 in response to PMA 
(Thalacker, F.W. and Nilsen-Hamilton, M., manuscript in 
preparation). 
The effect of TGF-)8 and Retinoic Acid 
on [^H]thymidine Incorporation 
Because retinoic acid and TGF-# both induced IIP73, we 
were interested in whether retinoic acid inhibits DNA 
synthesis in a manner similar to TGF-/3. However, we found 
that whereas TGF-# is a very potent inhibitor of DNA 
synthesis (up to 98% inhibition of DNA synthesis in CCL64 
cells after 24 h incubation), retinoic acid stimulated DNA 
synthesis in CCL64 cells (Table 3). Labeling indices for 
these treatments confirmed the results obtained from liquid 
scintillation counting. 
Regulation of the IIP73 Signal Transduction Pathway 
Because retinoic acid does not appear to depend on the 
TGF- p receptor to induce IIP73, we wished to determine 
Table 3. The effect of EGF, TGF-j8, retinoic acid and 
retinoyl-/S-glucuronide on incorporation of 
[^H]thymidine in CCL64 cells 
3H-TdR incorporated Labeling Index 
Addition Fold/control % of Maximum fold/control 
Control 1.0 (9) 0. 31 (3) 1.0 
EGF 4.44° (9) 1. 00 (3) 3.28 
TGF-J3 0.04® (9) 0. 0 (3) 0.00 
Ret. A. M 00
 
w
 0
 
(9) 0. 55 (3) 1.81 
Ret. Glue. 2.70° (4) 0. 64 (3) 2.11 
EGF (5 ng/ml), GI/TGF-/3 (1 Unit/ml), retinoic acid 
(10~®M) or retinoyl-^-glucuronide (lO^^M) were added to 
CCL64 cells plated on glass cover slips for 20-24 h before 
labelling with [^H]thymidine for 4-5 h in the presence of 
the additions indicated. Cover slips were fixed and 
[^H]thymidine incorporation was measured by liquid 
scintillation counting and by counting labeled nuclei in 
liquid film-covered cover slips. The fold/control value is 
the mean of these experiments. The numbers in parentheses 
show the number of experiments with two independent 

EGF (5 ng/ml), GI/TGF-/8 (1 Unit/ml), retinoic acid 
(10~®M) or retinoyl-/3-glucuronide (10~®M) were added to 
CCL64 cells plated on glass cover slips for 20-24 h before 
labelling with [^H]thymidine for 4-5 h in the presence of 
the additions indicated. Cover slips were fixed and 
[^H]thymidine Incorporation was measured by liquid 
scintillation counting and by counting labeled nuclei in 
liquid film-covered cover slips. The fold/control value is 
the mean of these experiments. The numbers in parentheses 
show the number of experiments with two independent 
estimates for each experiment. The paired Students t-test 
was used for statistical analysis. The analysis was done 
by comparing the values from control samples with the 
values for each growth modulator-treated sample.® 
°p < 0.005. 
^p < 0.01. 
°p < 0.05. 
^p < 0.1. 
®Where there are no asterisks, the p value was > 0.1. 
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whether the intracellular signals mediating induction of 
IIP73 by TGF-/3 and retinoic acid were the same. To 
determine whether the intracellular cAMP concentration 
could influence IIP73 expression, CCL64 cells were treated 
with forskolin or cholera toxin in the presence or absence 
of TGF-/3 and the effects on induction of IIP73 and PAI-1 
were measured. Elevation of intracellular cAMP by 
forskolin and cholera toxin had little effect on the basal 
or TGF-/3- and retinoic acid-induced levels of IIP73 (Table 
4). 
To determine whether induction of IIP73 by TGF-# and 
retinoic acid is through protein kinase C (PKC), we treated 
CCL64 cells with a high concentration of PMA (100 ng/ml) 
for 48 h to down-regulate protein kinase C and then treated 
the cells with TGF-# or retinoic acid. There was no 
significant decrease in the ability of TGF-/3 or retinoic 
acid to induce IIP73 after PKC down-regulation (Table 5). 
Down-regulation of protein kinase C had no significant 
effect on the ability of TGF-# to inhibit DNA synthesis but 
the induction of DNA synthesis by retinoic acid was blocked 
(Table 6). 
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Table 4. The effect of inducers of cAMP on induction of 
IIP73 by TGF-/9 
IIP73 area/cpn 
Addition fold over control 
control 1.0 (3) 
TGF-p 8.5 [6.9] (3) 
Forskolin 1.5 [0.1] (3) 
Forskolin + TGF-/3 3.7 [0.9] (3) 
control 1.0 (2) 
TGF-jS 16.8 (2) 
cholera toxin 0.8 (2) 
cholera toxin + TGF-/3 14.4 (2) 
CCL64 cells were plated in DMEM with 1.0% calf 
serum. Twenty-four h after plating the medium was changed 
to fresh DMEM with 0.5% calf serum. Twenty-four h later, 1 
Unit/ml GI/TGF-p or 10"®M retinoic acid, in combination 
with either SO/xM forskolin or 1 mM dibutyryl cAMP was 
added, and 3 h later the cells were labeled with 
[^®S]methionine for 4 h with the same factors present as 
during the preincubation. The fold/control values are 
means of 2 or 3 experiments, respectively. The numbers in 
brackets are the standard deviations for the experiments 
and the number in parentheses indicates the number of 
experiments. 
103 
Table 5. The effect of protein kinase C down-regulation 
on induction of IIP73 by TGF-/S and retinoic acid 
IIP73 area/cpm 
control-treated PMA-treated 
Addition fold over control 
control 1.0 1.0 
EGF 3.8 0.8 
TGF-/3 14.9 28.9 
PMA 0.3 5.0 
Retinoic Acid 12.7 11.8 
CCL64 cells were plated in DMEM with 1% calf serum. 
Eighteen h later the medium was changed to DMEM with 0.5% 
calf serum. Twenty-three h later either 0.1% MegSO or 100 
ng/ml PMA with 0.1% Me2S0 was added to the cells. After 
the 47 h pre-preincubation, the medium was changed to fresh 
DMEM with 0.2% calf serum and the cells were preincubated 
with 5 ng/ml EGF or 1 Unit/ml pTGF-/3 or 10 ng/ml PMA or 10" 
®M retinoic acid. Twenty-five h later the cells were 
labelled with [^®S]methionine for 4.3 h in the presence of 
the growth modulator present during the preincubation. 
This table details an experiment that is representative of 
3 experiments with treatments done in duplicate. 
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Table 6. The effect of PKC down-regulation on growth 
modulator stimulation of DNA synthesis 
control-treated PMA-treated 
Addition fold over control 
control 
EGF 
TGF-P 
PMA 
retinoic acid 
1.0 
1.9 
0.04 
1.3 
2.1 
1.0 
1.3 
0.12 
0 . 8  
0.5 
CCL64 cells were treated with 0.1% Me2S0 or 100 ng/ml 
PMA and 0.1% Me2S0 for 48 h. At the end of this period, 
the medium was removed, replaced with fresh DMEM with 0.2% 
calf serum and the indicated growth modulators: 5 ng/ml 
EGF, 1 Unit/ml GI/TGF-p, 10 ng/ml PMA and 10~®M retinoic 
acid. Twenty h later, the cells were labeled with 
[^H]thymidine for 4 h in the presence of the indicated 
growth modulators. The fold/control value represents the 
mean of three experiments with duplicates for each 
treatment. 
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DISCUSSION 
Retinoids and TGF-/3 can have similar effects on 
cellular proliferation and differentiation. TGF-/5 and 
retinoids can also have profound effects on the expression 
and activity of a wide variety of genes and proteins of 
cultured cells, especially genes and proteins associated 
with the extracellular matrix such as fibronectin and 
coJ.Iagen (15,23,24). TGF-# also stimulates expression of 
PAI-1 (18,21), plasminogen activator (33), and 
glycosaminoglycans (16). Retinoic acid causes medial 
epithelial cells to continue expression of EGF-receptors 
and fail to undergo programmed cell death (34), increases 
the rate of testosterone production by rat Leydig cells 
(35), induces transglutaminase gene expression by 
transcriptional regulation (36), and decreases alkaline 
phosphatase activity and mRNA levels and adenylate cyclase 
activity in osteosarcoma cells (37). 
TGF-/3 and retinoic acid are potent inhibitors of the 
proliferation of certain cells, especially cells of 
epithelial origin (9,11). These agents are both 
bifunctional because they can also stimulate proliferation 
of some cells (38,39). TGF~/9 was named because of its 
ability, in combination with EGF, to induce the growth of 
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non-neoplastic NRK cells, which are normally anchorage-
dependent, in soft agar (40). Retinoic acid, .pa in 
combination with any two of.TGF-#, EGF or PDGF, can also 
induce NRK cells to grow in soft agar in a defined medium 
(41). 
We were interested in determining whether retinoic 
acid could regulate expression of specific secreted 
proteins in a manner similar to TGF-#. Of particular 
interest to us was regulation of PAI-1 because of the role 
PAI-1 plays in association with proteins of the 
extracellular matrix. Our earlier experiments showed that 
retinoic acid did not significantly induce PAI-1 (Frederic 
W. Thalacker and Marit Nilsen-Hamilton, manuscript in 
preparation). Although we have seen induction of PAI-1 
synthesis and secretion by retinoic acid, in some 
experiments the induction was relatively small (about 2-
fold), and sometimes not seen at all (data not shown). We 
do not believe that retinoic acid is a major regulator of 
PAI-1 in CCL 64 cells. 
Retinoic acid induced the TGF-/9-inducible protein in 
CCL64 cells that we call IIP73. This response was specific 
for CCL64 cells. Retinoyl j9-glucuronide, which is a 
naturally occurring, water soluble retinoid with fewer 
toxic effects but very potent retinoid activity (28), also 
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induced IIP73. We did not see any protein secreted in 
response to retinoic acid in AKR-2B, BSC-1, or NRK cells 
(data not shown). TGF-/3 and retinoic acid both induced 
synthesis and secretion of IIP73. TGF-/3 also induces 
plasminogen activator inhibitor (PAI-1) and fibronectin in 
CCL64 cells. Retinoic acid can induce fibronectin in 
rabbit corneal keratocytes (fibroblasts) and in human 
keratinocytes cells (42,43). However, this induction does 
not occur in all cells. For example, retinoic acid did not 
induce fibronectin in CCL64 cells in this study. 
In some experiments TGF-/3 seemed to be a slightly 
better inducer of IIP73 than retinoic acid (Figure 1, Table 
1). However, when the retinoic acid solution was made up 
within days of it being added to the cells and maintained 
in the dark, there was no significant difference between 
the TGF-/9- and retinoic acid-induced IIP73 levels. The 
effects of retinoic acid and TGF-/3 on the rate of IIP73 
production were additive. 
Induction of IIP73 by TGF-/9 and retinoic acid depends 
on synthesis of mRNA and protein. This was evident from 
the results of experiments in which inhibitors of RNA and 
protein synthesis were found to block both the TGF-/3 and 
retinoic acid induction of IIP73. Treatment of CCL64 cells 
with the protein synthesis inhibitor cycloheximide 
108 
prevented Induction of IIP73 by either TGF-/3 or retinoic 
acid in CCL64 cells. This indicates that T6F-/3 and 
retinoic acid may induce another protein that in turn 
regulates IIP73 gene expression. 
Relatively few genes are known to be induced by 
retinoids. Era-1 (early retinoic acid) (44) has been 
cloned from F9 teratocarcinoma stem cells and is induced 
25-30-fold over a 48 h period. Protein synthesis 
inhibitors such as cycloheximide do not prevent Era-l mRNA 
induction after exposure to retinoic acid and dibutyryl 
CAMP has little or no effect on the level of Era-1 mRNA 
levels. Because cycloheximide prevents induction of IIP73 
by retinoic acid, IIP73 is probably not Era-1. IIP73 is 
not heavily glycosylated because treatment with tunicamycin 
has no effect on the of IIP73 or on the induction of 
IIP73 by TGF-/3 and retinoic acid. 
In contrast to TGF-/3, which is a potent inhibitor of 
DNA synthesis in CCL64 cells, retinoic acid stimulates DNA 
synthesis in CCL64 cells. Several groups have shown that 
retinoic acid can increase the binding of EGF to cells 
(45,46,47). Our data shows that, while the down-regulation 
of protein kinase C by long term incubation with PMA had no 
effect on the ability of TGF-/3 or retinoic acid to induce 
IIP73, it eliminates the stimulation of DNA synthesis by 
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retinoic acid. TGF-/3 is still a potent inhibitor of DNA 
synthesis after PKC down-regulation. These data suggest 
that retinoic acid may stimulate DNA synthesis by a 
mechanism that involves PKC but that it regulates IIP73 
through a different means. 
We have found that lung cells produce IIP73. We have 
not found IIP73 induction by AKR-2B, BSC-1 or NRK cells 
(data not shown). It has recently been shown that retinoic 
acid can induce TGF-#2 (7). Therefore, one explanation for 
many of the effects of retinoic acid is that it acts by 
stimulating an autocrine mechanism that involves induced 
TGF~iS. If retinoic acid acts by inducing TGF-)0 then we 
would expect to see that retinoic acid induces all of the 
proteins induced by TGF-jS. To determine whether this is 
so, we treated CCL64 cells with retinoic acid for various 
time periods and looked for the appearance of both PAI-1 
and IIP73. We have previously shown that PAI-1 is induced 
by CCIi64 cells in response to TGF-/3 and PMA (18) and that 
PAI-1 is induced by TGF-/3 before IIP73 (these proteins are 
maximally induced by TGF-/3 by 4 h and 24 h, respectively). 
If retinoic acid acted on CCL64 cells by inducing TGF-/3, 
then we would expect to see a sequential induction of PAI-1 
and IIP73. Over a 13 h time course, it can clearly be seen 
that, while there was a large induction of IIP73, there 
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was little if any change in the level of PAI-1. Similarly, 
fibronectin was induced by TGF-/3 but not by retinoic acid. 
A different approach to determine whether TGF-/3 is an 
obligatory component of the IIP73 signal transduction 
pathway was to use the Type 1 TGF-/3 receptor-minus mutant 
CCL64 cells, provided by Boyd and Hassaguë (31). We showed 
that, while TGF-/3 could not induce IIP73 in the mutant 
cells, retinoic acid induced IIP73. Chinkers' mink lung 
epithelial mutant CCL64 cell line (30), similarly could be 
induced only by retinoic acid and not by TGF-/3 to 
synthesize and secrete IIP73. This cell line also lacks 
the type I receptor (Philip Howe, Vanderbilt University, 
personal communication). These results show that retinoic 
acid does not need a TGF-/3/TGF-/3-receptor system to induce 
IIP73. 
To determine whether the TGF-jS and retinoic acid 
signal transduction pathways had any common features, we 
tested the effect of down-regulation of the protein kinase 
C receptor on their ability to induce IIP73 in CCL64 cells. 
We have found that down-regulation of protein kinase C by 
long-term exposure to high concentrations of PMA eliminates 
the ability of PMA to induce PAI-1 but has no effect on the 
ability of TGF-j8 to induce PAI-1 (Thalacker, FW and Nilsen-
Hamilton, M. manuscript in preparation). After down-regulation 
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of protein kinase C in CCL64 cells, both TGF-/3 and retinoic 
acid can induce IIP73 as well as in the absence of PKC down 
regulation. Whereas restimulation of down-regulated CCL64 
cells with PMA gave no PAI-1 induction compared with 
control levels, restimulation of down-regulated CCL64 cells 
with both retinoic acid and TGF-/S induced IIP73 to levels 
comparable to non down-regulated induction. Therefore, the 
induction of IIP73 by TGF-/S and retinoic acid does not 
depend on protein kinase C. 
Because we have shown that compounds that increase 
intracellular cAMP concentrations can decrease expression 
of PAI-1 in CCL64 and other cell lines, we tested the 
effect of forskolin (a diterpine activator of adenylate 
cyclase) or dibutyryl cAMP on induction of IIP73 by GI/TGF-
/3 or retinoic acid. Forskolin, cholera toxin and dibutyryl 
cAMP significantly lowered both the basal and TGF-)S-induced 
levels of PAI-1 synthesized by a variety of cell lines 
including CCL64 cells. However, none of these factors had 
a significant effect on either the TGF-/3- or retinoic acid-
induced levels of IIP73. These compounds also had no 
effect on the basal levels of IIP73. Therefore the level 
of expression of IIP73 in CCL64 cells is insensitive to 
increases in intracellular cAMP concentration. 
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TGF-/3 and retinoic can have similar effects on 
cellular growth and proliferation, differentiation and 
regulation of components of the extracellular matrix. Our 
results show that TGF-p and retinoic acid both induce IIP73 
production but have different effects on DNA synthesis. 
Our results also show that the pathway for regulation of 
IIP73 expression by retinoic acid is different than that 
for regulating DNA synthesis and PAI-1 by TGF-^. While 
induction of IIP73 by TGF-f and retinoic acid is not 
sensitive to protein kinase C down-regulation or to 
negative regulation by increased levels of intracellular 
cAMP, the induction of PAI-1 by TGF-/3 is inhibited by cAMP. 
IIP73 induction is prevented by inhibitors of RNA and 
protein synthesis whereas PAI-1 induction is not. Retinoic 
acid stimulation of DNA synthesis is inhibited by 
preincubation with PMA whereas induction of IIP73 in not. 
Thus our results show that retinoic acid specifically 
induces a 73 kDa protein in mink lung (CCL64) epithelial 
cells. Although this protein is also induced by TGF-/9, the 
mechanism of induction of IIP73 by retinoic acid does not 
involve TGF-/3. 
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GENERAL CONCLUSION 
I have shown that TGF-jS can specifically induce syn­
thesis and secretion of PAI-1 from 6- to 27-fold in AKR-2B, 
BSC-1, CCL64 and NRK cell lines and induce IIP73 up to 60-
fold from CCL64 cells. PMA can induce synthesis and secre­
tion of PAI-1 in selected cell lines, MEP from AKR-2B cells 
and a 62/65 kDa protein from NRK cells. The induction of 
PAI-1 by TGF-jS is sensitive to inhibitors of RNA synthesis 
(30) . 
Direct measurements of PAI-1 mRNA half-life by our­
selves (data not shown) and others show that PAI-1 has a 
half-life of 2 to 3 h (109). It is not known whether 
treatment by TGF-)S stabilizes the PAI-1 mRNA. Others have 
shown that cycloheximide, an inhibitor of protein synthe­
sis, had no effect on the induced levels of PAI-1 and could 
itself increase PAI-1 levels (110). These results indicate 
that the level of PAI-1 mRNA may be regulated by a nu­
clease, the levels of which are dependent on continuous 
protein synthesis. These results, and experiments with the 
PAI-1 protein that show a half-life for the protein alone 
in solution at less than 3 h (87), demonstrate tight regu­
lation of PAI-1 expression. Either overexpression or under-
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expression of proteinase inhibitors such as PAI-1 would 
dramatically effect the proteolytic balance of a tissue and 
the results of such a condition could manifest itself 
through problems such as excessive clotting, destruction of 
connective tissue, or neoplasia. Understanding the regula­
tion of PAI-1 at the cellular level will give us a better 
understanding of PAI-1*s role in extracellular proteolysis 
and could help us better understand growth and development 
of the whole organism. 
We have shown that treatment by TGF-/S induces PAI-1 
mRNA synthesis in NRK and BSC-1 cells and that the in­
creases in mRNA parallel changes in the level of secreted 
[35s]methionine-labelled PAI-1 protein that can be detected 
in conditioned medium. In addition, we have shown that the 
rate of initiation of transcription of the PAI-1 gene by 
TGF-/8 and PMA in NRK cells is also increased compared with 
the control-treated cells and that the increases in tran­
scription initiation rate, again, parallel similar in­
creases in the rate of production of [^®S]inethionine-
labelled PAI-1 protein detected in the conditioned medium 
of these cells. Therefore, the primary regulation of 
PAI-1 expression is at the level of transcription. 
The TGF-/3 signal transduction mechanism is still not 
known. Regulation may occur at the level of transcription 
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through specific responsive elements and transcription 
factors such as NF-1. This has been shown for the regula­
tion of the alpha 2(1) collagen gene (111). There are 
reports that a protein may be involved in the regulation 
of TGF-)9-induced mitogenesis in AKR-2B cells (107,108). 
However, preliminary experiments in our laboratory, using 
pertussis toxin uncouple the receptor/effector complex for 
G£, showed that pertussis toxin had no effect on the inhib­
itory signal of TGF-/3 in CCL64 and BSC-1 cells. Perhaps 
the signal transduction pathways for inhibitory and mito-
genic signals are different. 
We showed that PAI-1 gene expression could be regulat­
ed by TGF-j8 and PMA and that this regulation was through 
separate signal transduction pathways. While both TGF-/3 
and PMA induced PAI-1 in near term mink lung epithelial 
cells, down-regulation of PKC by long-term exposure to high 
concentrations of PMA did not affect the TGF-/3-induced ex 
pression of PAI-1 by CCL64 cells but lowered the PMA-
induced PAI-1 to basal levels. The TGF-/3 and PKC signal 
transduction pathways may be linked in some way, but our 
data shows that PKC is not required for induction of PAI-1 
expression by TGF-#. 
A major finding from our work is that increased intra­
cellular concentrations of cAMP can lower the basal activi­
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ty and expression of PAI-1 from a variety of cell lines. In 
addition, TGF-/S-induced levels of PAI-1 are also lowered 
but the extent of lowering is coordinate with the lowering 
of basal PAI-1 expression. Therefore, while other groups 
(98,99) state that increased cAMP lowers TGF-/S-induced 
expression of their gene of interest, I have demonstrated 
in this dissertation that cAMP has no effect on the extent 
of induction by TGF-/3, but instead affects the basal level 
of expression of PAI-1. Therefore, cAMP does not seem to 
regulate the TGF-/3 signal transduction cascade as the other 
reports have indicated. 
The effect of cAMP on basal activity may also be gene 
specific. For example, our data shows that, while basal 
levels of PAI-1 were lowered in response to cAMP, the basal 
levels of the 62/65 kDa protein secreted by NRK cells was 
unchanged while PMA-induced levels of the 62/65 kDa protein 
were significantly lowered. Both the basal and PMA-induced 
levels of MEP in AKR-2B cells are increased by cAMP. 
An analogous system that could illustrate what may be 
happening with part of the PAI-1 system was described 
recently by Quinn et al. (112). In this report they de­
scribed studies on PEPCK promoter deletion mutations and 
the deletions' effects on chloramphenicol acetyltransferase 
activity. PEPCK is normally induced by cAMP and, as ex­
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pected, deletion of the CRE resulted in loss of cAMP respon­
siveness and basal activity. However, in addition, they 
described several other cis-acting elements located near 
the CRE and the initiation site of the PEPCK gene, one that 
is a basal inhibitory element and two that are basal stimu­
latory elements. While little is known of the mechanism by 
which cAMP inhibits gene expression, I propose that there 
may be inhibitory counterparts to the CRE and CREB system 
that has been described for cAMP responses in certain 
genes. Most experimentation has been set up to look for 
positive responses to outside stimuli. While detection of 
inhibitory elements and inhibitory transcription factors 
may be more problematic, information on inhibition of gene 
expression would be extremely rewarding and valuable to our 
understanding of gene expression. 
The final area of signal transduction that we examined 
was to look at the effects of TGF-j8, PMA and retinoic acid 
on the induction of PAI-1 and IIP73 in CCL64 mutant cell 
lines that do not express the type I TGF-/3 receptor and 
whose proliferation are not inhibited by TGF-#. While TGF-
/8 had no effect on PAI-1 levels in both RIB (14) and MLEM 
(113) mutant cells, PMA was an excellent inducer of PAI-1. 
The level of induction was approximately that of PAI-1 from 
the CCL64 cells tested in the same experiment. In addi­
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tion, while TGF-/3 had no effect on IIP73 levels in RIB or 
MLEM cells, retinoic acid was able to induce IIP73. The 
results from these two experiments indicate that the TGF-# 
receptor is necessary for induction by TGF-# but that the 
receptor is not necessary for induction of PAI-1 by PMA or 
IIP73 by retinoic acid. Therefore, the type I receptor 
mediates the TGF-/3 induction of PAI-1 and IIP73 in CCL64 
cells. 
The specific roles of the type II and type III TGF-# 
receptors in CCL64 cells are still not defined. It is 
possible that these receptors, while able to bind TGF-/8 
with high affinity, are no longer "hooked up" to the TGF-p 
signal pathsways. Activated and functioning type II and 
type III receptors may only be are necessary during a 
specific period of development (for example, from day 13 to 
day 15 in mouse development, during organogenesis of the 
lung). After the development "window" is over, the tissue 
may have turned off the type II and type III receptors in 
favor of the possibly more tightly regulated type I recep­
tor. 
The mechanism by which TGF-# inhibits DNA synthesis is 
not clear. The near term mink lung epithelial CCL64 cells 
are the most sensitive to the inhibitory effects of TGF-/3 
that have been studied. The inhibitory effects of TGF-/S on 
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these epithelial cells could be a reflection of the effect 
of TGF-/3 on the embryonic lung from which these cells were 
isolated. TGF-/9 could induce production of ECM in lung 
that could be necessary for proliferation in early develop­
ment but that later in development acts to inhibit prolif­
eration. 
Antibodies to a synthetic peptide corresponding to the 
amino-terminal 30 amino acids of mature TGF-^l can detect 
TGF-#1 in A549 human lung carcinoma cells as well as var­
ious mouse and human cells and tissues (114). While TGF-/31 
has been found in the developing mouse lung (115), little 
or no TGF-/31 is found in the adult lung. By contrast, 
intense localization of TGF-/31 is seen inside adult mouse 
kidney distal tubule epithelial cells and placenta and 
outside pancreas and uterus (116) . TGF-/31 mRNA is present 
in day 10 mouse liver and is the primary source of TGF-/31 
mRNA in embryos through day 14. There was no detectable 
TGF-/S1 mRNA on day 16 of mouse fetal development (117). 
Embryonic mouse lung also expresses high levels of EGF 
receptor although this expression seems to be transient 
(from day 13 to day 15 of development). EGF receptors are 
found in developing mouse kidney from day 11 through day 14 
(118). EGF precursor immunoreactivity has been found in 
the bronchiole tubules (epithelial cells) of 15 day embry­
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onic lung. However, no EGF precursor mKNA was found in this 
same tissue although both protein and mRNA were found in 
some nearby mesenchymal cells (119). EGF made by the 
mesenchymal cells may act on the bronchiole tubules through 
a paracrine mechanism. EGF affects lung morphogenesis at 
early stages of development by stimulating epithelial 
branching (120). 
There is no report of the presence of TGF-# receptors 
in embryonic lung tissue. However, to my knowledge, this 
question has not been examined although it seems reasonable 
to believe the receptors may be present. Our results from 
the CCL64 near term mink lung epithelial cells combined 
with the evidence that EGF, EGF-receptor, and TGF-/8 (and 
potentially TGF-/3 receptors) are present in rodent embryon­
ic lung suggests the EGF (TGF-a) and TGF-# may regulate 
some aspects of embryonic lung development. During the 
period of rapid growth and cellular proliferation of the 
lung (day 13), the epithelium originates from tracheal buds 
that proliferate and form tubular structures, possibly in 
response to EGF or TGF-a. EGF and TGF-a may also induce 
more net proteolytic activity at this same time. At the 
end of this period of rapid growth, which is accompanied by 
induction of genes coding for proteinases, expression of 
TGF-/3 in the lung could, in combination with EGF, result in 
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induction of expression of extracellular matrix proteins, in 
particular TIMP and PAI-1. This expression would result in 
net proteolytic inhibitor activity. TGF-f may also inhibit 
expression of proteinases such as collagenase and plasmino­
gen activator in developing lung. 
We have shown that TGF-/8 and EGF synergistically 
induce PAI-1 in CCL64 cells and that ÏGF-/3 can induce 
extracellular matrix proteins such as fibronectin and 
collagen. This expression of PAI-1, and other proteinase 
inhibitors such as TIMP, could create an extracellular 
matrix environment for the cell that promotes stability and 
adherence to the substratum rather than rapid growth. This 
possibility is supported by the evidence that collagen is 
the direct mediator of TGF-j8-induced inhibition of growth 
in NRK cells (95). TGF-/3 induces fibronectin and collagen 
in CCL64 cells (25). Whether there is a direct link be­
tween TGF-/S-induced inhibition of DNA synthesis and induc­
tion of collagen in CCL64 cells is not known. TGF-/3 in­
duces normal human bronchial cells to undergo squamous 
differentiation which leads to irreversible inhibition of 
DNA synthesis. Thus, an inhibitor of proliferation in lung 
can also induce terminal differentiation. 
Because TGF-/3 and retinoic acid can induce components 
of the ECM (collagen, fibronectin, and proteoglycans) and 
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because TGF-j9 and retinoic acid can both be potent inhibi­
tors of cellular, especially epithelial cell growth and 
proliferation, we wondered whether the effects of retinoic 
acid would be similar to those of T6F-j9 on gene expression 
and proliferation in cells under our culture conditions. 
We found that while both TGF-/3 and retinoic acid 
induce IIP73 in CCL64 cells, these two growth modulators 
regulate other CCL64 cells processes differently. For 
example, TGF-/3 but not retinoic acid induces fibronectin 
and PAI-1. Retinoic acid stimulates DNA synthesis while 
TGF-/3 is an extremely potent inhibitor of DNA synthesis by 
these cells. While retinoic acid can induce TGF-^2 (121), 
it is unclear whether TGF-/3 modulates nuclear retinoic acid 
receptor levels. Therefore, it seems that TGF-j9 and retin­
oic acid are acting differently on this cell system. 
Induction of IIP73 by TGF-/S and retinoic acid is not 
reduced by down-regulation of PRC. In addition, TGF-p- and 
retinoic acid-induced expression of IIP73 are not affected 
by compounds that raise intracellular cAMP concentrations. 
This is in contrast to PAI-1, which has both basal and 
induced levels of expression lowered by cAHP. The differ­
ences in regulation may reflect differences in genes. 
IIP73 could be without a responsive element that could make 
IIP73 expression sensitive to cAMP. 
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What role, if any, IIP73 may play in organogenesis is 
not known although the role of retinoids in limb bud forma­
tion is becoming increasingly clear (57). When IIP73 is 
isolated and characterized functionally, the relationship 
of the the ability of both TGF-/3 and retinoic acid to 
induce IIP73 can be more fully examined. 
Unresolved is the role of in mediating the effect 
of TGF-jS on PAI-1 and IIP73 gene expression. G^ has been 
implicated in lowering TGF-^-induced mitogenesis and GTPase 
activity (107). Inhibition of G^ could result in an 
increase of basal cAMP that should result in a lowering of 
expressed PAI-1. We found no effect of pertussis toxin in 
TGF-j9-induced expression of PAI-1. Our results indicate 
that Gj^ is not involved in the TGF-j8-induced expression of 
PAI-1. Thus, while G^ is a component of the TGF-# induced 
stimulation of DNA synthesis in AKR-2B cells, the signal 
for TGF-/S-induced expression of PAI-1 is not mediated by 
G^, indicating that the signals for proliferation and 
specific gene expression are regulated differently. 
Future work on this project can involve identifica­
tion and further characterization of IIP73. While purifi­
cation and characterization (peptide sequencing) will 
eventually provide the identity and function of IIP73, it 
is possible that IIP73, like PAI-1, is associated with the 
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ECM. One approach is to test proteins of similar molecular 
weight for which an antibody is available. For example, 
one candidate is vitronectin, with a similar (75,000 kDa) 
to IIP73. 
Current experimentation in our laboratory includes 
isolation of the PAI-1 gene from CCL64 cells in order to 
study the regulatory elements both upstream and within the 
PAI-1 gene, with special emphasis on defining the mechanism 
for the synergistic interaction of TGF-# and EGF in induc­
tion of PAI-1. We might expect some form of TRE and possi­
bly an NF-1 site in addition to sequences that might con­
tain cAMP basal regulatory elements such as have been 
described for PEPCK. We are also developing PAI-1 expres­
sion vectors to examine the role PAI-1 may play in allowing 
anchorage-independent growth. It is possible that overex-
pression of PAI-1 would allow formation and stabilization 
of ECM around the suspended cell providing some signal 
which could start proliferation. 
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